Novel Application of Melt Extrusion and Additive Manufacturing on Developing Diverse Dosages by Zhang, Jiaxiang
University of Mississippi 
eGrove 
Electronic Theses and Dissertations Graduate School 
2019 
Novel Application of Melt Extrusion and Additive Manufacturing 
on Developing Diverse Dosages 
Jiaxiang Zhang 
University of Mississippi 
Follow this and additional works at: https://egrove.olemiss.edu/etd 
 Part of the Pharmacy and Pharmaceutical Sciences Commons 
Recommended Citation 
Zhang, Jiaxiang, "Novel Application of Melt Extrusion and Additive Manufacturing on Developing Diverse 
Dosages" (2019). Electronic Theses and Dissertations. 1720. 
https://egrove.olemiss.edu/etd/1720 
This Dissertation is brought to you for free and open access by the Graduate School at eGrove. It has been 
accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of eGrove. For more 
information, please contact egrove@olemiss.edu. 
 NOVEL APPLICATION OF MELT 
EXTRUSION AND ADDITIVE 
MANUFACTURING ON 
DEVELOPING DIVERSE DOSAGES 
 
 
 
A 
Dissertation presented in the partial fulfillment of requirements for the Doctoral of Philosophy 
degree in the Department of Pharmaceutics and Drug Delivery  
The University of Mississippi 
 
 
 
 
 
 
 
by 
JIAXIANG ZHANG 
December, 2018 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright Jiaxiang Zhang 2018 
ALL RIGHTS RESERVED 
ii 
ABSTRACT 
New drug product development is a time consuming and costly process. One of the 
significant challenges is the poor aqueous solubility of many active pharmaceutical ingredients 
(APIs). Among those techniques, hot-melt extrusion(HME) is optimal for pharmaceutical solid 
dispersion development because of it free of using an organic solvent,  easy scale up, and suitable 
for continuous processing with ensured optimal quality control.  
Inter-individual variability is always an issue when treating patients of different races, 
genders, ages, pharmacogenetics, and pharmacokinetic characteristics. Also, developing new 
drugs is complicated and expensive, so optimizing the bioavailability, or therapeutic effect of 
existing drugs has gained much interest. Additive manufacturing (AM) is a new alternative 
solution for the development of controlled release dosages because it can produce personalized or 
unique dosage forms and more complex drug-release profiles.  
In this dissertation, a comprehensive study of patient-focused drug development by 
combining HME and 3D printing technologies has been conducted. The feasibility of conjugating 
HME and 3D printing was studied first. Then a series of the polymer screening studies were 
conducted to determine the widely available drug loaded printable filaments for fused depositional 
modeling (FDM) based 3D printer, fast release, extended release, and controlled release dosage 
were produced via different polymer matrix and structure design. In addition, due to the highly 
customized structure of 3D printed tablets, the release kinetics and correlation of the drug release 
to the structure has been studied, which demonstrated a comprehensive understanding the in vitro 
drug release mechanisms and kinetics from the 3D printed dosages. After the series studies of 
HME and 3D printing, the optimization of the oral drug administration also been conducted via a 
specific 3D structure design, which can rapidly effective and maintains a long therapeutic time 
synchronously.  
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INTRODUCTION  
Solid dispersions represent a promising formulation approach undertaken by many 
pharmaceutical scientists to improve the bioavailability of active pharmaceutical ingredients (API) 
with poor aqueous solubility [1][2][3]. Hot-melt extrusion (HME) is one of the preferred methods 
in pharmaceutical solid dispersion development. This is because the technology can generate 
extrudates/ granules with favorable properties. In addition, it is free from the use of organic 
solvents and suitable for continuous processing [4][5][6]. 
HME was first used in the plastics and rubber industry. However, since the 1970s, the use 
of HME has been promoted in pharmaceutical research [7][8]. The pharmaceutical use of HME is 
currently under investigation as a method for increasing the release rate of poorly water-soluble 
APIs. The bioavailability of such APIs are enhanced by melt-mixing them with hydrophilic, water-
soluble polymers [9][10]. Apart from increasing the bioavailability of an API, HME can be used 
to develop modified-release drug systems with delayed drug delivery characteristics and the ability 
to mask the bitter taste of an API [11][12]. Moreover, HME can be easily coupled with other 
technologies, such as high-pressure homogenization, to prepare solid lipid nanoparticles [9] and 
nanocrystals [13]. It can also be used with high-pressurized carbon dioxide to enhance milling 
efficiency and to prepare a floating drug delivery system by creating porous extrudates [14][15]. 
In recent years, researchers have started exploring the conjugation of HME with three-dimensional 
(3D) printing to prepare pharmaceutical dosage forms [16][17][18]. 
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3D printing is a layer-by-layer production of 3D objects with the help of digital designs 
[11]. It is also known as additive manufacturing (AM). AM equipment and materials were 
developed in the early 1980s, mainly for chemistry, optics, and robotics research [19]. The first 
powder-based free-form fabrication using 3D printing methods became available in 1993 at the 
Massachusetts Institute of Technology (MIT) [20], in which a standard inkjet head was used to 
print binders onto loose powders in a powder bed.  
Compared with the traditional process of manufacturing dosage forms, 3D printing can 
create complex products, personalized products, and products made for immediate consumption 
[21]. Based on the advantages offered by 3D printing technology, interest in this technique within 
the pharmaceutical industry has grown over the last few years. This is reflected in the increasing 
number of scientific reports and patents describing the pharmaceutical applications of 3D printing. 
Recently, the U.S. Food and Drug Administration (FDA) approved the first 3D-printed (3DP) 
orally disintegrating tablet SPRITAM1 (levetiracetam), which was manufactured based on the 
ZipDose Technology (Aprecia Pharmaceuticals, Langhorne, PA, USA).  
The traditional process of manufacturing pharmaceuticals involves a complex downstream 
procedure, which includes milling extrudates, sieving, compressing, and coating. However, 3D 
printing technology can streamline these processes. Compared to the traditional process of 
manufacturing pharmaceutical products, combining HME and 3D printing into a continuous 
process can offer advantages. These include increased solubility and bioavailability of drugs, as 
well as production of more complex-structured dosage forms and personalized drug products. In 
addition, combining the two technologies can simplify the downstream process and make it more 
effective and economical (Figure. 1). In particular, the FDA encourages drug manufacturers to 
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produce oral solid dosage forms that meet the increasing demands of oral drug delivery, in terms 
of API bioavailability and drug release characteristics, in a continuous and controlled process [22].  
 
Figure 1. Schematic of the combination of HME and 3D process. 
Based on the advantages of coupling the two technologies, the elementary steps involved 
in producing dosage forms by continuous HME-3D printing are as follows: 1) dosage form design 
and conversion to a printer-readable format; 2) preparation of raw materials (such as powders, 
particulates, granules, or pastes); 3) preparation of hot-melt extruded filaments; 4) cooling of the 
filaments; 5) 3D printing; and 6) removal of printed material and downstream processes such as 
cooling, drying, and packing. However, for continuous pharmaceutical HME and 3D printing, 
extruding the 3D-printable filaments is a very important elementary step, along with dissolving 
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the poorly water-soluble API in molten polymeric excipients and mixing them to improve the 
bioavailability of the API.  
In this thesis, HME and 3D printing technologies were conjugated for the highly 
customized or personalized development. For the 1st chapter, the feasibility studies of the 
combining the two technologies were conducted. Moreover, the preliminary screening of the 3D 
printable filaments formulation were studied as well. To understand the different of the 3D printed 
and conventional dosages, the compression studies of size, hardness, and in vitro drug release 
between 3D printed tablets and direct compressed tablets were conducted as well. For the 2nd 
chapter, characterization and evaluation of a series filament formulations were studied. After we 
optimized the filaments for pharmaceutical 3D printing process, the correlation of the drug release 
profiles with the 3D structure of the tablets, as well as the drug release mechanism and kinetics 
from the 3D printed matrix were studied in the 3rd chapter. Finally, the optimization of  oral drug 
administration by using optimized filament formulation and 3D printing technologies were 
discussed in the 4th chapter. 
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CHAPTER 1 
COUPLING 3D PRINTING WITH HOT-MELT EXTRUSION TO 
PRODUCE CONTROLLED-RELEASE TABLETS 
1.1. Introduction 
3D printing is an emerging technology which has been introduced to the medical area few 
decades ago, and has been applied to pharmaceutical area in recent years. Previous studies have 
used powder/binder-based biodegradable polymers, such as polyethylene oxide/polycyclooctene 
[23], ethyl cellulose (EC), hydroxypropyl methylcellulose (HPMC) E50, polyvinylpyrrolidone 
K30 [24], and Eudragit1 L100 (Rathbone, 2008), to print pharmaceutical dosage forms. Recently, 
biodegradable polymer filaments, prepared from HPMC K100M CR [25] and polyvinyl alcohol 
[16][17], were manufactured by 3D printing.  
The present study investigated the use of different types of pharmaceutical polymers to 
prepare fused filaments suitable for 3D printing of a desired pharmaceutical formulation. The main 
objectives of this study were as follows: 1) to couple fused deposition modeling (FDM)-based 3D 
printing with HME technology to print controlled-release tablets, 2) to screen different grades of 
pharmaceutical polymers suitable for 3D printing based on the HME-fused filaments’ physical and 
chemical properties, and 3) to study the drug release profiles of 3DP tablets in comparison to those 
of directly-compressed milled extrudate and physical-mixture tablets.
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1.2. Materials and methods 
1.2.1. Materials 
Acetaminophen (APAP) (Spectrum Chemical, New Brunswick, NJ, USA) was used as the 
model API. APAP is a crystalline Class I Biopharmaceutics Classification System drug (high 
permeability, high solubility) with a melting point of 169–170 °C. BenecelTM HPMC E5, KlucelTM 
HPC EF and LF, and AqualonTM EC N14 were donated by Ashland Inc. (Covington, KY, USA). 
Soluplus1 was donated by BASF (Ludwigshafen, Germany). Eudragit1 L100 was donated by 
Evonik Industries (Essen, Germany). All other reagents were of either high-performance liquid 
chromatography (HPLC) or analytical grade.  
1.2.2. Methods  
1.2.2.1. Formulations  
Table 1. Formulation of different polymers 
Formulation Drug (w/w) Polymer (w/w) Disintegrator (w/w) 
I 0 100% PLA - 
Stage 1 
I-1 30% 70%HPC LF - 
I-2 30% 70%HPC EF - 
I-3 30% 70%HPMC E5 - 
I-4 30% 70%EC N14 - 
I-5 30% 70%Soluplus  - 
I-6 30% 70% Eudragit L100  
Stage 2 
II-1 30% 35% HPMC E5+35% EC N14 - 
II-2 30% 35% HPMC E5+35% HPC EF - 
II-3 30% 35% HPMC E5+35% HPC LF - 
II-4 30% 35% HPMC E5+35% Soluplus - 
II-5 30% 35%HPMC E5+35% Eudragit L100 - 
II-6 30% 35% EC N14+35% Soluplus - 
II-7 30% 35%HPC LF+35% EC N14 - 
Stage 3 
III-1 30% 45.5% HPMC E5+19.5% EC N14 5% 
III-2 30% 45.5% HPMC E5+19.5% HPC EF 5% 
III-3 30% 45.5% HPMC E5+19.5% HPC LF 5% 
III-4 30% 50% HPMC E5+15% Soluplus 5% 
III-5 30% 50% HPMC E5+15% Eudragit L100 5% 
III-6 30% 50% EC N14+15% Eudragit L100 5% 
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Polylactic acid (PLA) without drug deposition was used as the reference standard. Various 
formulations were prepared, in which the polymers were used at different ratios. The procedure 
was divided into three different stages. The first strategy was to use a single polymer at 30% w/w 
of the drug load (I 1–6) (Table 1). The second strategy was based on the results of the 3-point bend 
test and 3D printing process; thus, a binary combination of polymer blending ratios was used to 
improve the mechanical properties of the filaments (II 1–7). The third strategy was based on the 
results of the second strategy and an in vitro drug release study. The combinations of polymer 
blending ratios were further modified or a super disintegrate (Kollidon CL-F) was added to the 
formulations to improve both the mechanical properties of the filaments and the dissolution 
properties of the 3DP tablets. A physical mixture (API + polymer) was tumble-mixed using 
MaxiblendTM (Globe- Pharma, New Brunswick, NJ, USA) at 25 rpm for 20 min, followed by 
sieving with a US#30-mesh screen to remove any aggregates in the mixture.  
1.2.2.2. HME process  
 
Figure 2. Standard screw configuration of Thermo Scientific 11mm twin screw co-rotating 
extruder. 
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The extruder (Thermo Fisher Scientific, Waltham, MA, USA) used in this work was a co-
rotating, twin-screw extruder with 11- mm diameter screws. It had an L/D of approximately 40 
and eight electrically heated zones. The feeding zone temperature was controlled by an external 
circulation heater. The HPMC formulations were extruded at 180 °C; however, all the other 
formulations were extruded at 140–160 °C in all the zones. The physical mixtures were extruded 
at a screw speed of 50 rpm with a standard screw configuration (Figure. 2). A 2-mm round-shaped 
die was used to extrude filaments for 3D printing. In addition, a conveyor belt was used to cool 
and straighten the filaments to feed them into the 3D printer. Extra filaments were collected and 
milled to compare 3DP tablets with tablets made by HME.  
1.2.3. Filament characterization  
 
Figure 3. TA analyzer and 3-point bend test.  
Samples of extruded filament were collected and cut into 5-mm segments. Next, a TA-
XT2i analyzer (Texture Technologies, Hamilton, MA, USA) and a TA-95N 3-point bend probe 
set (Texture Technologies) were used to test the brittleness of the extruded filaments (Figure. 3). 
Each filament was placed on the sample holder of the 3-point bend tester with a 25-mm gap. The 
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moving speed of the blades was 10 mm/s until they reached 15 mm under the samples. Fifteen 
filaments of each formulation were tested and Exponent software version 6.1.5.0 (Stable Micro 
Systems, Godalming, UK) was used for data collection and analysis.  
1.2.4. Differential scanning calorimetry (DSC)  
A Diamond DSC system (PerkinElmer, Waltham, MA, US) was used to study drug 
crystallinity and characterize drug miscibility with the extrudates. Two to 5 mg of sample was 
hermetically sealed in an aluminum pan and heated from 40 to 200 °C at a rate of 10 °C/min. Ultra-
purified nitrogen was used as the purge gas at a flow rate of 50 mL/min in all the DSC experiments. 
Data were collected and analyzed with Pyris software (PerkinElmer).  
1.2.5. Thermogravimetric analysis (TGA)  
TGA was performed by using a PerkinElmer Pyris 1 TGA calorimeter to determine the 
thermal stability of APAP and the polymers during the HME processing. The samples were placed 
in an open aluminum pan and heated from 30 to 300 °C at a rate of 20 °C/min. Ultra-purified 
nitrogen was used as the purge gas at a flow rate of 25 mL/min. Data were collected and analyzed 
using the Pyris software. Percentage mass loss and/or onset temperatures were then calculated.  
1.2.6. 3D printing  
 
Figure 4. a) Dimensions of the 3D printing tablets; b) layer and printing path view of the tablets. 
10 
 
The model tablets were designed using Microsoft 3D Builder (Microsoft, Redmond, WA, 
USA) and converted to .gcode files using CURA software (version 15.04; Ultimaker, 
Geldermalsen, The Netherlands). Tablet dimensions (diameter, 10 mm; thickness, 4.5 mm) were 
determined based on the drug load (Figure 4). Tablets were fabricated with the extruded filaments 
using a commercial FDM-3D printer (Prusa i3 3D desktop printer, Prusa Research, Prague, Czech 
Republic) with an extruder, which had an E3D V6 hot end and a 0.4-mm nozzle (figure 5). The 
following printer settings were found to produce the best tablets: a standard resolution with the 
raft option activated and an extrusion temperature of 200 °C. The other settings used were as 
follows: bed temperature, 50 °C; printing speed, 50 mm/s; nozzle traveling speed, 50 mm/s; layer 
height, 0.10 mm; and outside shell thickness, 0.4 mm. The infill percentage was set at 100% to 
allow printing of tablets with optimum characteristics. The dimensions and weights of the 3DP 
tablets were then measured.  
 
Figure 5. Schematic picture of 3D printer extruder. 
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1.2.7. Preparation of tablets by direct compression  
Based on the weights of the 3DP tablets, 400 mg of physical mixtures of each formulation 
were compressed into tablets using a 0.375-in. die at 300 bar (PM tablets). On the other hand, the 
extruded filaments were milled and compressed into tablets under the same conditions (EXT 
tablets).  
1.2.8. Tablet characterization  
1.2.8.1. Assessment of tablet morphology  
A VWR1 digital caliper (VWR1, PA, U.S.) was used to determine the diameters and 
thicknesses of the tablets and a Canon 60D camera was used to image the tablets (Canon, Tokyo, 
Japan). Cross- sectional images of the 3DP tablets, extrudate tablets, and directly compressed 
tablets were taken using scanning electronic micros- copy (SEM). 
1.2.8.2. Determination of tablet strength  
A standard tablet hardness tester (VK200; Agilent Technologies, Santa Clara, CA, USA) 
with a maximum force of 35 kp was used to measure tablet hardness. Six tablets from each group 
of tablets were tested.  
1.2.9. In vitro drug release study 
Drug release from the 3DP, EXT, and PM tablets was determined using a United States 
Pharmacopeia (USP)-II dissolution apparatus (Hanson SR8-plusTM; Hanson Research, 
Chatsworth, CA, USA). Dissolution tests were conducted as per the US Pharmacopeial standards 
using Simulated Intestinal Fluid TS (without pancreatin) (pH 6.8), which is representative of the 
small intestinal fluid of humans. Each experiment was carried out in triplicate using 900 mL of the 
dissolution medium at 37±0.5 °C for 24 h. The paddle speed was set at 50 rpm. Samples were 
taken at 0.5,1, 2, 4, 6, 8, 10, 12, and 24 h and analyzed. The amount of released APAP was 
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determined by HPLC (Waters Corp., Milford, MA, USA) at 246 nm and analyzed using Empower 
software (version 2, Waters Corp.).  
1.3. Results and discussion  
1.3.1. Preliminary study of raw materials  
The TGA results showed that APAP and the physical mixtures degraded only at 
temperatures above 350 °C, which indicates that the drug and polymer matrix would not degrade 
at the HME processing temperature (140–180 °C) nor at the operating temperature (200 °C) of 3D 
printing (Figure 6). Although shear was applied during the HME process, it was not high and did 
not cause APAP degradation. This was because the die pressure and torque applied during the 
process were low.  
 
Figure 6. TGA results for raw materials and physical mixtures. 
DSC is a thermoanalytical technique for measuring phase transitions in a sample as a 
function of temperature, when more heat flows to the sample than to the reference. The DSC curve 
for pure APAP showed a peak at 172 °C (Figure 7). A heating method was utilized for the physical 
mixtures in the DSC analysis. As expected, all the physical mixtures showed an obvious peak at 
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around 170 °C; however, there were peak shifts of approximately 2–3 °C, possibly owing to 
interactions between APAP and the polymers. During the heating process, all the extruded samples, 
except formulation III-6 (50% EC), had smaller peaks (or no peaks at all) than the physical 
mixtures did. This indicates that APAP dispersed or dissolved in the molten polymer matrix during 
the HME process to form a homogeneous solid dispersion. However, for formulation III-6, owing 
to the hydrophobic properties of EC N14 and, hence, its low miscibility with APAP, the APAP 
only partially dissolved in the EC polymer matrix. As a result, most the APAP was dispersed as 
its crystal form in the matrix.  
 
Figure 7. DSC results for physical mixtures and milled extruded filaments. 
1.3.2. Fabricating 3D-printable filaments  
As shown in Figure. 8 very brittle filaments were broken by the feeding gear. Similarly, 
filaments that were too soft were squeezed aside by the feeding gear. Viscosity is an important 
parameter to consider when formulating filaments for 3D printing. Therefore, we carried out 
optimization studies on the formulation composition and HME processing parameters. Most 
commercially available 3D printers were designed for the plastics industries. As a result, they 
mostly print plastic-like filaments, such as acrylonitrile butadiene styrene and PLA because they 
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possess proper stiffness, toughness, and melt viscosity. In the present study, we used PLA as a 
reference to compare the differences between commercially available filaments and extruded 
filaments. 
  
Figure 8. Filament properties during 3D printing process. a) Filaments too brittle; b) filaments 
good for printing; c) filaments too soft. 
One of our goals was to fabricate filaments with adequate mechanical property using a 
pharmaceutical HME process suitable for use with most commercially available 3D printers. 
Stiffness is one of the most important parameters for judging whether a filament could be well fed 
into a 3D printer or not. It is used to describe the mechanical properties of a structure, as the “load” 
needed to achieve a certain “deformation”.  
Stiffness =  
𝐿𝑜𝑎𝑑
𝐷𝑒𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑜𝑛
 
There are varieties of possible configurations of the “load” (force, stress, arbitrary groups 
of forces, etc.) that acts on a structure. In addition, there is an infinite number of possible points in 
a structure, where deformation (displacement, angle, radius, curvature, etc.) can be measured [26]. 
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A strong filament will require a high breaking force. However, the filaments we manufactured 
were not homogenized. In addition, their diameters varied because of the factors involved in the 
HME process (e.g., feeding rate and conveyor belt speed); therefore, stress (ratio of force to cross-
sectional area) was taken to represent the actual stiffness of a filament. Furthermore, in this study, 
the Figure 7. DSC results for physical mixtures and milled extruded filaments. breaking stress was 
considered as “load” and the breaking distance was considered as “deformation”.  
Brittleness is another important parameter for judging filaments. The ability of a structure 
to deform plastically before it fractures is called its ductility. “Brittle” is the term used to describe 
a structure that has low ductility [27]. According to this definition, when force is applied to a brittle 
structure, it breaks without significant deformation (breaking distance). The 3-point bending 
flexural test is used to assess the breaking force, breaking distance or time (which is the time a 
blade touches a material to the time it breaks), and the flexural stress of a material. In this study, 
“stiffness” (breaking stress) and “brittleness” (breaking distance) were used to qualify the 
filaments. The stiffness of the extruded filaments was calculated from the breaking force and 
breaking distance values obtained from the 3-point test.  
The aim of this study was to manufacture filaments with good mechanical and rheological 
properties, as well as tablets with desired drug dissolution and release properties. More than 10 
batches of each filament type were printed and tested to ensure that they could be well fed into the 
printer and be printed for more than 6 times. Filaments that passed this test were referred to as 
being “Adequate” for 3D printing. Only 3DP tablets formulated using the third strategy were used 
the in vitro drug release study; therefore, only the necessary data are shown in this section to clarify 
the limitations of the 3DP operation.  
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Figure 9.  Filament 3-point bend test results of a) breaking distance and b) stiffness (breaking 
stress). 
As shown in Figure 9, in the first stage of extrusion of single-polymer formulations, we 
found that the HPMC filaments displayed high stiffness (high breaking stress) and toughness (high 
breaking distance); however, the filaments had rough surfaces. The HPMC filaments could be fed 
into the printer; however, printing was difficult because of their rough surfaces and high melt 
viscosities. The EC filaments displayed good stiffness; however, they were very brittle (small 
breaking distance) and got easily broken by the feeding gear. The HPC LF and EF filaments were 
too soft and flexible to be fed into the printer. However, Soluplus1 and Eudragit1 L100 could not 
be extruded into filaments at high temperatures (140 °C), as they melted completely.  
Table 2.  Filaments 3-point bend test results. (n=10, mean±SD) 
 
Force 
(g) 
Distance 
(mm) 
Stress 
(g/mm2) 
Strain 
(%) 
Property 
I 1206.25±18.92 2.15±0.14 15740.58±235.69 80.54±0.23 Adequate* 
III-1 445.73±30.80 4.58±0.30 2722.14±325.36 234.23±9.81 Adequate 
III-2 183.99±45.13 5.98±0.35 2676.83±284.91 72.30±3.63 Adequate 
III-3 243.75±18.19 5.32±0.27 2371.49±180.01 84.08±0.69 Adequate 
III-4 584.62±49.27 2.02±0.50 5610.81±377.69 92.16±0.94 Brittle 
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III-5 621.86±36.05 1.28±0.49 4647.50±279.18 102.69±0.97 Brittle 
III-6 283.42±21.67 0.82±0.38 1517.19±114.48 267.49±1.98 Adequate 
II-3 320.13±26.64 5.38±0.72 1676.56±132.01 243.99±10.21 Soft 
II-6 283.54±22.54 4.82±0.66 1633.29±129.26 236.92±3.72 Soft 
II-7 98.65±6.67 4.48±0.44 578.83±48.31 233.97±3.35 Soft 
I-3 673.86±61.66 4.66±0.46 6056.44±551.90 87.00±0.85 Adequate 
I-4 323.29±45.14 0.92±0.28 2941.28±404.92 94.05±0.52 Adequate 
*Adequate: 10 batches of each filament were tried during printing, if it can be printed without 
break or squeezed aside more than 6 times, we define the filaments is “adequate” for 3D printing.  
For the second stage of the formulation screening, HPMC and EC were blended with HPC, 
Soluplus1, and Eudragit1 to prepare filaments for 3D printing. As seen in Figure 9 and Table 2 
PLA had the highest force, stiffness, and stress values. In addition, filaments prepared from it were 
perfectly printed. Although the breaking distances of filaments II-3, II-6, and II-7 were high 
(>4.48±0.44 mm), their breaking stresses were approximately 1700 g/mm2, which indicated that 
the filaments were too soft to be fed into the 3D printer. No high breaking stress limits were 
observed; however, for the HPMC formulation, the filaments were too hard and rough, which 
cause high friction during the feeding process. In 3rd stage study, 5% w/w Kollidon CL-F were 
added into the formulation, which can smooth the surface of the filaments, especially the HPMC 
based formulations, which can reduce the friction during feeding of the 3D printing process and 
made the filaments printable. In summary, a filament must simultaneously have high a breaking 
stress, a high stiffness, and a long breaking distance to allow for optimum printing. 
During the printing process, all formulations prepared using the third strategy could be 
printed; however, formulation III-6 was somewhat brittle and was occasionally broken by the 
feeding gear. Formulations II-3, II-6, and II-7 were soft and had low breaking forces and stresses; 
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however, their breaking distances were large, which indicated softness of the filaments. 
Formulation I-3 produced the stiffest filaments and had favorable mechanical properties for 3D 
printing. The data indicate that, to fabricate extruded filaments for use with different models of 3D 
printers, the filaments should be adequately stiff (breaking stress > 2941 g/ mm2) and brittle 
(breaking distance > 1 mm), as these can help in achieving optimal feeding and printing conditions. 
Furthermore, the roughness and rheological properties of filaments can influence the 
printing process. High-melt viscosity can affect both extrusion and the 3D printing process. It can 
result in the production of filaments with rough surfaces, which can block the nozzle or disrupt 
extrusion during the printing process. However, further rheological studies on the filaments should 
be carried out. 
1.3.3. Tablet morphology studies 
In the formulation screening using the third strategy, all the formulations prepared were 
printed well; however, the tablets prepared from formulations III-4 and III-5 were much darker in 
color. This could have been due to degradation of the drug and/or the polymer(s) during the thermal 
processing. As a result, further work was not carried out on the two formulations. Images from the 
tablets morphology study and SEM analyses revealed that the 3DP tablets had smooth surfaces 
and a tight structure. Moreover, hardness testing and theoretical geometry calculations showed that 
the 3DP tablets had a higher density and hardness than the directly compressed tablets did. The 
mean hardness of tablets prepared from formulation III-1 was 24.7 ±4.2 kp. However, the hardness 
of 3DP tablets prepared from formulations III-2, III-3, and III-6 were above the upper limit of the 
hardness tester and much higher than the hardness of the directly compressed tablets (17– 28 kp). 
The volume of each cylindrical tablet was calculated as follows:  
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𝑉 =
𝜋𝐷2
4
∗ ℎ Eq 1 
 
Where the D is the diameter of the tablets, and h is the thickness of the tablets. Thus, the 
theoretical density of a tablet was calculated according to the following equation:  
 
𝜌 =
𝑚
𝑉
=
4𝑚
𝜋𝐷2 ∗ ℎ
 Eq 2 
Where the m is the weight of the tablet. As shown in Table 3, the theoretical density of 
3DP tablets is much higher than that of directly compressed tablets. In addition, tablets with high 
hardness and density values show delayed disintegration and slow drug release after administration.  
Table 3.  Geometry study of the tablets. (n=6, arithmetic mean±SD) 
Tablets 
Diameter 
(mm) 
Height 
(mm) 
Weight 
(mg) 
Density 
(mg/mm3) 
Hardness 
(kp) 
I 3DP 10.15±0.09 4.50±0.04 375±27 1.029 >35 
III-1 
3DP 10.11±0.42 4.46±0.04 416±16 1.162 24.7±4.2 
EXT 9.53 4.79±0.01 ~400 1.171 5.4±1.1 
PM 9.53 4.86±0.02 ~400 1.154 18.0±1.4 
III-2 
3DP 10.03±0.45 4.42±0.10 436±12 1.248 >35 
EXT 9.53 4.62±0.01 ~400 1.213 7.1±0.8 
PM 9.53 4.73±0.01 ~400 1.185 14.4±0.9 
III-3 
3DP 10.22±0.21 4.47±0.02 440±9 1.199 >35 
EXT 9.53 4.58±0.03 ~400 1.224 7.5±0.4 
PM 9.53 4.78±0.01 ~400 1.173 20.9±1.1 
III-6 
3DP 10.24±0.18 4.21±0.19 408±14 1.178 >35 
EXT 9.53 5.83±0.02 ~400 0.958 6.8±0.9 
PM 9.53 5.09±0.01 ~400 1.102 13.6±0.9 
As shown in Figure 10, the intensity of the yellow color of the formulations was in the 
order of 3DP > EXT > PM, which reflects changes in the crystalline state of the API after the 
thermal processes. According to the DSC results, most of the API dissolved in the molten polymer 
matrix. Physical mixtures contained the excipients in their amorphous states because of the mixing 
and high shear stress involved in the melt-extrusion process. Although no mixing and shear stress 
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are involved in the 3D-printing process, the high processing rate involved can cause the melting 
matrix to change to an amorphous state.  
 
Figure 10.  a) 3D-printed tablets; b) 3D-printed tablets (left), extrudate tablets (center), physical 
mixture tablets (right). 
The different formulations contained similar components and therefore had similar 
structures. As a result, the SEM data for only one formulation have been presented (Figure 11). 
The upper images (Figure. 11a) show the internal layers of the tablets. Since the tablets were split 
for analysis, the single-layer structure was destroyed; therefore, an uneven layer is seen. The 
images at the center (Figure.11b) show a perfect layer structure of the tablets; however, the layers 
are not homogenous, which may have resulted from variations in filament diameter during the 
HME process. Constant processing parameters will get homogenous filaments, or a constant 
diameter of the filaments. The variations could have been due to the constancy of feeding speed, 
melt viscosity, or conveyor belt speed. The images in the lower panel (Figure. 11c) show some 
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spaces between the particles forming the tablets, which may have been caused by the high-melt 
viscosity of the materials. Furthermore, the spaces in the tablets could indicate that the 3D-printing 
process did not occur smoothly. Variations in the weights of the tablets were <0.6% and within the 
accepted range of <5% according to the USP 2091 guidance on weight variation of dietary 
supplements.  
 
Figure 11. SEM images of formulation. a) 3D-printed tablets; b) direct-compressed physical 
mixture tablets; c) direct-compressed extrudate tablets.   
According to the SEM images obtained for the PM and EXT tablets, no single particulate 
could be seen in the 3DP tablets, which indicate that the tablets were continuously structured and 
had homogenous compositions. Because of the special structure of the 3DP tablets, they 
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disintegrated at a slower rate than the other two types of tablets did, or perhaps the 3DP tablet can 
only dissolve, rather than disintegrate. It was observed that the particle size of the EXT tablets was 
larger than that of the PM tablets. Therefore, the expected order of tablet disintegration rate, and 
hence, drug release rate, was EXT > PM > 3DP. 
1.3.4. In vitro drug release study  
The 3DP, directly compressed EXT, and PM tablets were evaluated for their drug 
dissolution rates. Poorly water-soluble APIs can disperse or dissolve in polymer matrices to form 
solid dispersions or solutions during the HME process [28]. As expected, all the 3DP tablets 
showed good extended drug release rates because of their high density and hardness, which were 
due to their tight 3D structure (Figure 12). Faster drug release rates were observed with the directly 
compressed EXT and PM tablets. Formulations III-1, III-2, and III-3 showed 80% drug release 
within 6–10 h, whereas the 3DP tablets released APAP over a longer period (III-1: 87%, III-2: 
63%, and III-3: 72% drug release after 10 h, respectively). The EXT tablets released APAP faster 
than the PM tablets did. This was because the APAP dissolved in the hydrophilic polymer matrix 
and formed a solid dispersion during the HME process. All the groups of tablets except those 
prepared from formulation III-6 (hydrophobic matrix) achieved 100% drug release within 24 h of 
the in vitro dissolution study. This proved that no API or excipient degradation occurred during 
the HME or 3D printing process.  
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Figure 12. In vitro drug release study of 3D-printed tablets, direct-compressed extrudate tablets, 
and physical mixtures. 
EC is soluble in various solvents but barely soluble in water. The PM tablets directly 
compressed from formulation III-6 showed an 80% drug release in 1 h, because the tablets 
disintegrated rapidly in the dissolution medium. However, the EXT tablets prepared from 
formulation III-6 showed an extended drug release rate (55.48% at 12 h and 72.19% at 24 h). 
Formulation III-6 can be considered as a partially solid dispersion. This is because, in that 
formulation, APAP was dispersed in an EC polymer matrix only partially due to the thermal 
processes. This is also evident in the DSC data for the milled extrudates prepared from formulation 
III-6 (Figure 7). The 3DP tablets from formulation III-6 released only 8.90% of APAP within 24 
h because of its continuous and homogenous 3D structure. The tablets did not disintegrate easily 
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and as a result, APAP was barely released from the matrix. The release rate of APAP from the 
3DP and EXT tablets was controlled due to its entrapment in the EC hydrophobic matrix.  
As mentioned previously, the 3DP tablets barely disintegrated in the dissolution media 
because of their tight 3D structure. After the 24-h in vitro drug release study, formulations III-2 
and III-3 dissolved; however, formulation III-1 produced some flocculent precipitates in the 
dissolution media. Moreover, formulation III-6 maintained its original shape almost throughout 
the study period.  
Due to the structural design of the 3DP tablets, the printed tablets prepared from the 
different formulations displayed identical 3D structures and had approximately similar densities 
and hardness. The differences among the drug release rates from the various 3DP tablets were 
mainly attributable to the different formulation compositions.  
The drug release profiles for all the 3DP tablets are shown in Figure 12. It was observed 
that drug release rate was in the order of III–1 > III–3 > III–2 > III-6. Formulation III-1 was a 
combination of hydrophobic and hydrophilic polymers and was expected to have a better extended 
drug release rate than formulations III-2 and III-3. This is because the API was dispersed mainly 
in the HPMC rather than in the EC polymer matrix, as was confirmed by the DSC results. The 
APAP peak was more notable in the thermogram for formulation III-6 than it was in the other 
thermograms (Figure 7). The total amounts of APAP released from formulations III-1, III-3, and 
III-4 were similar and were each much higher than the APAP amount released from formulation 
III-6, which supports the above hypothesis. HPMC E5 is more hydrophilic than HPC LF and EF 
are. In addition, HPC LF has a larger molecular weight (~95,000 Da) than EF has (~80,000 Da); 
thus, the drug release rates from the formulations were in the following order: III–1 > III–3 > III–
2 > III-6. 
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1.4. Conclusions  
In this study, we successfully fabricated solid-dispersion filaments with the API dissolved 
or dispersed in a polymer matrix by HME technology, which was suitable for FDM-based 3D 
printing. Extruded filaments prepared using binary polymer blends of HPMC E5 and EC N14 with 
either HPC EF and LF, Soluplus1, or Eudragit1 L100 were printed well. We also set up a 
preliminary standard to evaluate the physical and mechanical properties of the filaments that were 
suitable for 3D printing using a 3-point bend test. The 3DP tablets had a more consistent and 
elegant appearance, as well as better extended drug release profiles than the directly compressed 
tablets did. This study clearly demonstrates that coupling FDM-based 3D printing with HME 
offers a potential new method for manufacturing personalized-dose medicines and/or tablets, 
which can be prepared when needed. 
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CHAPTER 2 
DEVELOPMENT AND EVALUATION OF THE PHARMACEUTICAL 3D 
PRINTABILITY OF HOT MELT EXTRUDED CELLULOSE-BASED FILAMENTS 
2.1. Introduction 
Nowadays, polymeric oral-controlled dosage development has been considered to be an 
economical and immediate consumption to reducing the inconvenience caused by the frequent 
dosing of conventional tablets, which can improve patients’ quality of life (QOL) [29]. 
Furthermore, increasingly rising additive manufacturing (AM), also as known as 3D printing 
technology has provided a practical solution for individual, complex consumption for oral-
controlled Drug delivery systems (DDSs). 3D printing is the layer-by-layer production of 3D 
objects from digital designs[11], and it is more efficiencies and economical compared with 
developing new active pharmaceutical ingredients or excipients, new manufacturing process, or 
protocols. 3D printing technology provides an alternative means of engineering release profiles by 
control of spatial distribution within a given polymer composition rather than creating a new host 
material[30].  
Solid dispersions represent a promising formulation approach for overcoming today’s 
major challenge in the pharmaceutical industry of developing bioavailable solid dosage form for 
more than 50% of drug candidates that are poorly water soluble[31][3][32]. Processing 
technologies such as spray drying (SD), hot-melt extrusion (HME), KinetiSol® dispersing (KSD), 
freeze-drying (FD), rotary evaporation (RE), co-precipitation (CP), centrifuge vacuum drying 
(CVD), and microwave technology [33] can be used for preparing the solid dispersions. Hot-melt 
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extrusion(HME) is the preferred option in pharmaceutical solid dispersion development because 
of the favorable powder properties generated from this technology, the absence of organic solvents 
in processing, the small footprint of the equipment, ease of increasing batch size, scalability from 
pilot to industrial setting, and suitability of continuous processing. [4][6] 
HME is a term that the pharmaceutical industry adopted to differentiate it from traditional 
oral dosages manufacturing techniques, such as direct compression and tableting[5]. It involves 
the use of single- but mostly twin-rotor extruders for the processing of usually water-soluble 
polymeric excipients, mixing them while molten with APIs to affect partial or total API dissolution 
and pumping the homogeneous mixture through a die to form an extrudate, where the API exists 
in a totally or partially dissolved but (in both cases) stable form[34][10].  
HME was firstly used to plastic and rubber industrial since the 1930s. Pharmaceutical hot 
melt extrusion (HME) is currently investigated by both industry and academia as a method for 
increasing the release rate of poorly water-soluble APIs and potentially enhance their 
bioavailability, by melt -mixing them with hydrophilic, water-soluble polymers[8]. HME helps to 
overcome poor bioavailability of active pharmaceutical ingredients (API), as well as creating new 
modified-release drug systems and can serve as a unit operation to taste mask the bitterness of a 
tablet. At the same time, an increasing body of literature is concerned with the production of 
controlled release dosages by melt-mixing readily water-soluble APIs with rate-controlling 
polymers[34].  
Compared to the traditional pharmaceutical products manufacturing process, combine 
HME and 3D print technology as a continuous process will highlight each respective advantages: 
1) increase the poorly water-soluble drugs solubility and bioavailability; 2) produce more complex 
structured dosages and personalized drug products. What`s more, combine this two technology 
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reduce the downstream process which will be more efficient and economical. In particular, the 
Food and Drug Administration (FDA) encouraged drug-makers to produce solid oral dosages that 
meet the increasing demands of oral drug delivery regarding bioavailability of the active 
pharmaceutical ingredients (API) and drug release characteristics, in a continuous and controlled 
process[22]. Several biodegradable polymers have been investigated by researchers, such as 
polyethylene oxide/polycyclooctene [23], ethyl cellulose (EC), hydroxypropyl methylcellulose 
(HPMC) E5[35], polyvinylpyrrolidone K30[24], and Eudragit® L100 [36], to print pharmaceutical 
dosage forms. Varieties of polymers and combination can be used for 3D printing. However, 
researchers rarely focus on the characterization and evaluation the filaments are suitable for 3D 
printing or not. This study aimed to characterize and the evaluate both physical and chemical 
properties of filaments designed for fuse depositional manufacturing additive manufacturing and 
produced by hot melt extrusion (HME) technology.  
2.2. Materials and Methods  
2.2.1. Materials  
Acetaminophen (APAP) (Spectrum Chemicals, Gardena CA) was chosen as the model API. 
APAP is a crystalline BCS I drug with a melting point of 169°-170°C. AquaSolve™ hypromellose 
acetate succinate (HPMCAS) LG and HG, Benecel™ hydroxypropyl methylcellulose (HPMC) E5 
and K100M, Klucel™ Hydroxypropyl cellulose (HPC) EF and HF, and Aqualon™ ethylcellulose 
EC N14 were donated by Ashland®. Diluted water was used for all formulations and solutions. 
All other reagents were of either HPLC or analytical grade. 
2.2.2. Formulation  
A variety of formulations have been tried and separated into 2 different stages in this study 
in total. Firstly, 7 different kinds and grades of pure polymer without drug-loaded polymer were 
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extruded. Then 7 formulations of single polymer with 30% W/W drug loading were tried. 
(Polylactic acid (PLA) without drug loading was used as reference) (table. 4) To get physical 
mixtures, raw materials were prepared and mixed by using MaxiblendTM (GlobePharma, New 
Brunswick, NJ, USA) at 25 RPM for 20 min, after passing through a US#30 mesh screen to remove 
any aggregates that may have formed.  
Table 4. operation parameters and process trends for the 7 different formulations during HME 
process.  
 T (℃) Torque (N*m) Pressure (bar) 
without drug PM without drug PM without drug PM 
HPC EF 140 140 12 2.4 100 7 
HPC HF 170 150 5.55 2 28.5 11.5 
HPMC E5 190 150 8.4 4.26 47 23.5 
HPMC K100M N/A 190 N/A 6.7 N/A 77.5 
HPMCAS LG 200 150 6.6 2.16 19 9 
HPMCAS HG 200 150 4.6 4.32 6 10 
EC N14 150 150 7.2 4 45 20 
 
2.2.3. Pre-formulation Analysis  
2.2.3.1. Thermogravimetric analysis (TGA) 
All samples were prepared with open aluminum pans. A Perkin-Elmer TGA 1-Pyris 
(PerkinElmer, Inc, USA) were used to heat samples from 30 °C to 500 °C at 20 °C/min. Ultra-
purified nitrogen was used as a purge gas with a flow rate of 25 ml/min. Data collection and 
analysis were performed using PerkinElmer PyrisTM software and % mass loss and/or onset 
temperature were calculated. 
2.2.3.2. Differential scanning calorimetry (DSC) 
All samples were prepared with TA aluminum pans and lids (Tzero) with an average 
sample mass of 5–10 mg. Measurements were performed on a TA Instruments Discovery DSC 25 
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(TA Instruments, USA) with a heating rate of 10 °C/min, a heat-cool-heat circle was used to for 
the conventional physical mixtures. Ultra-purified nitrogen was used as a purge gas with a flow 
rate of 50 ml/min for all the experiments. Data were collected and analyzed with TA Instruments 
Trios software. All melting temperatures were reported as extrapolated onset unless otherwise 
stated.  
2.2.3.3 Polarized light microscopy (PLM) 
Polarized light microscopy observations were conducted with a polarizing microscope 
LEICA DM 2500 P, equipped with a video-recorder camera and a hot thermostated stage TMS 94 
(Linkam Scientific Instruments Ltd.) connected to the temperature programmer. All samples was 
heated from 25°C to 220°C at 10 °C/min, and videos were recorded from the start until cooling to 
room temperature.  
2.2.4. Preparation of the 3D printable filaments 
A Thermo Fisher Scientific twin screw co-rotating process 11 extruder with standard screw 
design and an Antaris II inline NIR probe inserted as a PAT tool was utilizing the 3D printable 
filaments preparation. All physical mixtures were extruded at 50 RPM, and the temperature setting 
for different formulations are listed in table 4. A 2 mm round shape die used for extrusion filaments 
for a 3D printer. A conveying belt was used to cooling and make the filaments straight in order to 
feed into the 3D printer.  
2.2.5. Characterization and evaluation the filaments 
2.2.5.1. Mechanical properties  
Flexibility, brittleness and stiffness properties of the filaments were evaluated to represent 
the printability of the filaments. For Flexibility and brittleness analysis, extruded filament samples 
were collected and cut into 5mm in length. TA-XT2 analyzer (Texture Technologies Corp, New 
York, USA) and TA-95N 3-point bend probe set with 25mm supporting gape were used to test the 
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brittleness of the extruded filaments. The blades moving speed is 10 mm/s until reach 15mm below 
the samples. Each single formulation filaments were repeated 15 times. Breaking distance and load 
force/stress data were collected and analyzed by Exponents software. For stiffness analysis, 
filaments samples were collected and cut into 5 mm in length, the experiment set up was same as 
the 3-point bend test, but the sample holder was a solid flat metal. The blade will cut into the 
sample for 35 % shape change (0.6 mm), and breaking stress/force data were collected. Each single 
formulation filaments were repeated 15 times as well. 
2.2.5.2. Crystallinity of the extruded filament  
All the extruded samples were milled using a home-style coffee grinder and then sieved 
using 40 mesh. A single heat circle was used to check the melting properties of the milled extrusion 
samples. 
2.2.5.3. Powder X-ray diffraction  
XRPD analyses were performed on a Bruker D8 Focus™ diffractometer with Cu radiation. 
Diffracted radiation was detected by a LynxEye™ Position Sensitive Detector. The X-ray 
generator power was set to 40 kV and 40 mA. A silicon standard was analyzed to check instrument 
alignment. The sample was packed on a 25 mm poly(methyl methyacrylate) (PMMA) holder to 
form a disc-shaped specimen. The specimen was analyzed with a continuous scan from 4° to 40° 
2θ. 
2.2.5.4. Rheology analysis  
Raw materials and milled extrudates were prepared for the rheology analysis. A dynamic 
viscosity rheometer was used for frequency sweep studies, which was running at 170 °C from 1-
100 rad/s for all samples. A temperature sweep all conducted for all the samples at 1 rad/s from 
100 °C to 180 °C. 
32 
 
2.2.6. 3D printing 
The tablets were designed using Microsoft 3D Builder (Microsoft, Redmond, WA, USA) 
and converted to .gcode files using CURA software (version 15.04; Ultimaker, Geldermalsen, The 
Netherlands). Tablet dimensions (diameter, 10 mm; thickness, 4.5 mm) were determined based on 
the drug load. Tablets were fabricated with the extruded filaments using a commercial FDM-3D 
printer (Prusa i3 3D desktop printer, Prusa Research, Prague, Czech Republic) with an extruder, 
which had an E3D V6 hot end and a 0.4-mm nozzle. The following printer settings were found to 
produce the best tablets: a standard resolution with the raft option activated and an extrusion 
temperature of 200 ˚C. The other settings used were as follows: bed temperature, 50˚C; printing 
speed, 50 mm/s; nozzle traveling speed, 50 mm/s; layer height, 0.10 mm; and outside shell 
thickness, 0.4 mm. The infill percentage was set at 100% to allow printing of tablets with optimum 
characteristics. The dimensions and weights of the 3DP tablets were then measured.  
2.2.7. Assessment of tablet morphology 
A VWR1 digital caliper (VWR1, PA, U.S.) was used to determine the diameters and 
thicknesses of the tablets, and a Canon 60D camera was used to image the tablets (Canon, Tokyo, 
Japan). Cross-sectional images of the 3DP tablets, extrudate tablets, and directly compressed 
tablets were taken using electronic scanning micros- copy (SEM).  
2.2.8. Determination of tablet strength 
A standard tablet hardness tester (VK200; Agilent Technologies, Santa Clara, CA, USA) 
with a maximum force of 35 kp was used to measure tablet hardness. Six tablets from each group 
of tablets were tested. 
2.2.9. In vitro drug release study 
Drug release from the 3DP tablets was determined using a United States Pharmacopeia 
(USP)-II dissolution apparatus (Hanson SR8-plusTM; Hanson Research, Chatsworth, CA, USA). 
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Dissolution tests were conducted as per the US Pharmacopeial standards using Simulated Intestinal 
Fluid TS (without pancreatin) (pH 6.8), which is representative of the small intestinal fluid of 
humans. Each experiment was carried out in triplicate using 900 mL of the dissolution medium at 
37±0.5 ˚C for 24 h. The paddle speed was set at 50 rpm. Samples were taken at 0.5,1, 2, 4, 6,8, 10, 
12, and 24 h and analyzed. The amount of released APAP was determined by HPLC (Waters Corp., 
Milford, MA, USA) at 246 nm and analyzed using Empower software (version 2, Waters Corp.). 
2.3. Result and discussion  
2.3.1. Thermal stability of the materials 
Thermal behavior of the pure APAP and each of the polymer matrix has been studied 
through TGA. The APAP presents a mass loss step starting around 260˚C which is attributed to 
the decomposition of the chemical structure of APAP. The mass loss recorded during the applied 
thermal protocol is continuous, and the final residue is 3.8%. All of the polymer excipients showed 
better thermal stability compared to the API, which won`t degrade until heat above 360 ˚C (figure 
13). As mentioned in section 2.2.3 and Table 4, the process temperature was all below 200 ˚C, 
which means the high process temperature will not cause the degradation both of the API as well 
as the polymers.  
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Figure 13. Thermal degradation graph of the APAP and polymer excipients. 
2.3.2. Polarized light microscope (PLM)  
PLM has been widely used to determine the melting behavior and crystalline 
transformation of all raw materials and physical mixtures[37]. Limited by the space, one of the 
same polymer matrix was shown in figure 14. The needle-shaped pure APAP shows the crystalline 
structure at room temperature, which is melted above 174 ˚C and completely transformed to the 
amorphous states. For HPC formulations, at the room temperature, the HPC matrix also showed 
crystalline structures as well, however, due to the particle size and crystalline shape we can easily 
tell the difference of APAP and HPC particles. Once heated above the melting point, the APAP 
can lose its crystalline structure but there still some HPC particles stayed in semi-crystalline shape, 
which indicating HPC matrix may have an issue to form an amorphous solid dispersion with APAP.  
For HPMC formulations, the polymer particles showed no crystalline structures, but there have 
some unmelted polymers after heating. In order to have the ASD, mixing zones (kneading blocks) 
are required to help the mixtures transfer from crystalline to amorphous. HPMCAS particles were 
not shown the crystalline structure, and the physical mixture can be completely molten while 
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APAP was dissolved and dispersed into the polymer matrix. For EC formulation, due to the thick 
and opaque molten mixtures, it is hard to visually confirm APAP was dispersed into the polymer 
matrix or not. DSC and PXRD studies were carried out to confirm the transformation and 
miscibility of the APAP with the polymer matrix. 
 
Figure 14. The melting behaviors and crystalline transformation under PLM. 
2.3.3. Extrusion 
Polymer without drug loading was extruded for reference objectives. However, due to the 
large molecular weight, HPMC K100M can`t be extruded below 220℃ with the standard screw 
design at 50 rpm. For the extrusion of the drug-loaded filaments, multiple in-line NIR spectra were 
collected continuously for monitoring the extrusion process. As shown in figure 15, multiple 
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spectra for each formulation except HPMC K100M grades were perfectly overlapped which 
proved the filaments were homogeneous and the high reproducibility of the extrusion process. Due 
to the massive molecular weight and high melt viscosity, the HPMC K100M grade formulation 
still hard to extrusion which also is confirmed by the high torque and die pressure during the 
extrusion process. Compared with the raw NIR spectrum with the pure API and polymers, we 
found that the peak area around 6000 cm-1 can be used to both qualify and quantify the APAP in 
the extrudates. The raw spectrum of extrudates showed that the signal at this range was decreased 
while the 2nd derivative of the spectrum showed that peaks were slightly shifted to the lower energy 
side, which indicates the interaction between the APAP and the polymer matrix (figure 16). The 
APAP might act as the plasticizer and formed hydrogen bonds thus lowering the energy of the 
system during the extrusion process. 
 
Figure 15. the raw inline NIR spectrum collected during the extrusion process. 
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Figure 16. the 2nd derivative of the collected inline NIR spectrum during the extrusion process. 
The extrusion parameters were recorded as well and presented in figures 17. Both the 
torque and die pressure, as well as the lowest extrudable temperature, will decrease when adding 
30 % w/w APAP into the formulation, which indicating drug loaded physical mixtures represent 
good extrudability compared to the polymers without drug loading. AS observed from the 
mechanical characterization of the filaments, the extrudability and mechanical property were 
correlated. The higher extrusion torque and die pressure, the stronger and stiffer filaments will be 
obtained.  
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Figure 17 a) Process torque and b) die pressure of polymer without drug loading and with 30% 
APAP loaded formulations during HME process. 
2.3.4. Filaments evaluation  
The primary objective of this work is to manufacture the drug-loaded filament that can be 
widely used by a variety of FDM based 3D printers. Several physical and chemical 
characterizations were conducted in this work to determine the appropriate properties of the 
filaments can be printed. In the present study, we used PLA as a reference to compare the 
differences between commercially available filaments and extruded filaments. 
2.3.4.1. Crystallinity  
DSC studies were preformed to determine the crystallinity transformation during the 
thermal process. All the physical mixtures were heat and cool, then heated again, and apparently 
melting peak was observed during the first heating ramp which indicating the initial crystalline 
structures of the API. During the 2nd heating ramp, the melting peaks were disappeared except the 
HPC EF formulation showed the attenuated melting peak (figure 18 a)), which indicates the API 
was completely or partially dissolved or dispersed into the polymer matrix. All the extruded 
filaments were milled and applied for DSC analysis as well. As shown in figure 18 b), it showed 
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the similar results as the PM 2nd heating ramp. The HPC EF, HF and the EC formulation still 
showed the enthalpy of the melting which means there still consists the APAP crystalline, but it 
was attenuated compared to the melting enthalpy of their physical mixtures. All in all, the HME 
process allows conversion of API to amorphous form or dispersion of API in molecular level, 
which can result in enhanced bioavailability.  
 
Figure 18. the DSC result of the a) physical mixtures and b) milled extruded filaments. 
The FTIR techniques have been widely used in the analytical chemistry area especially in 
the organic compounds and the polymer analysis[38]. For APAP, it has the alcohol and amide 
functional groups which shall has the absorption peak around 3350 cm-1 and 3200 cm-1, while the 
polymers has no nitrogen functional groups (figure 19 a)). As shown in figure 19 b), the APAP 
spectrum shows obviously the existence of the alcohol and amide groups. However, in the 
extrudates, HPC formulation still shown the -OH peak which means the APAP was just mixed 
with the polymer and in the other formulations, both the -OH and -NH peaks were decreased or 
disappeared which may due to the molecular level mixing or formation of the hydrogen bonds 
during the HME process. 
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Figure 19. FTIR spectrum of the a) raw materials and b) milled extruded filaments. 
X-ray powder diffraction (XRD) has been used for phase identification of crystallinity can 
provide information in unit cell level[39]. The extrudates were finely ground and homogenized. 
As shown in figure 20, the HPC EF, HF, and EC N14 formulation still show the crystalline 
structures of the APAP in the formulation, which indicating the poor miscibility of the APAP with 
such 2 matrixes. The XRD, FTIR and DSC data cross verified the crystalline transformation of the 
APAP during the HME process, APAP can be easily dissolved or dispersed into the HPMC and 
HPMCAS polymer matrix and form amorphous solid dispersions. On the other hand, APAP was 
hard to form an amorphous solid dispersion with HPC or EC matrix even with the help of the high 
temperature and mechanical force from the HME process. 
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Figure 20. PXRD curve of the APAP and milled extruded filaments. 
2.3.4.2. Mechanical properties of the filaments  
The printability of different formulations were predominated by the mechanical and 
rheology properties of the extruded filaments. Filaments shall have adequate flexibility as well as 
strong enough to be printed. The FDM based 3D printing was developed from the plastic industry, 
and the PLA is one of the most widely used commercially available material on the market. In this 
work, PLA plastic was selected as the reference materials to evaluate the mechanical and 
rheological properties of the drug-loaded extruded materials.  
The three-point bend test is a classic experiment in mechanics, used to measure Young’s 
modulus of material in the shape of a strip, bar, or stick and so on. The material, of length L, rests 
on two supports and is subject to a concentrated load at its center[40]. 
Flexibility and toughness are two of the most critical parameters to determine the 
mechanical properties for judging whether a filament could be well fed into a 3D printer or not. In 
this work, flexibility can be defined that the tolerance of the filament the bending without breaking. 
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Moreover, the good toughness can be defined that when the filament subjected to the load, it breaks 
without significant plastic deformation. “toughness” is the term used to describe a structure that 
has high ductility[27]. The 3-point bend test is used to assess the breaking force, breaking distance 
or time (which is the time a blade touches a material to the time it breaks), and the flexural stress 
of a material. In this work, here the loading stress is used to represent the flexibility, and the 
breaking distance is used to represent the toughness of the filaments.  
One of the primary purposes of this work was to produce filaments with adequate 
mechanical and rheological properties, as well as print tablets with expected drug release profiles. 
During 3D printing process, ten batches of each filament have been tried to ensure that they could 
be well fed into the hot end and be printed without more than six failures.  Filaments that passed 
this test were referred to as being “Adequate” for 3D printing. In this work, it was observed that 
the HPC LF and HF filaments were too soft and flexible for the 3 point bend test as well as to be 
fed into the printer. Only HPMC E5, both HPMCAS HG and LG grades and EC N14 formulations 
can be successfully printed; therefore, only the necessary data are shown in this section to clarify 
the limitations of the 3DP operation.  
As shown in Figure 21 a), all the listed filaments showed poor toughness compare to the 
reference materials; the HPMC filaments displayed similar flexibility while the other filament was 
not. The HPMC E5 filaments displayed proper flexibility (breaking stress>995.3 g/mm2) and 
toughness (breaking distance=1.389 mm); It seems HPMC K100M filaments showed proper 
mechanical properties and could be fed into the printer; however, printing was difficult because of 
the fraction caused by its rough surface and high viscosities at 200 ˚C. The EC filaments displayed 
neither flexible or robust (small breaking distance=0.341 mm) and got easily broken by the feeding 
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gear. Both HPMCAS grades were flexible than EC formulation but showed poor toughness, and 
these two filaments can be easily broken during the feeding process.  
 
Figure 21. a) 3 point test results of the breaking distance and stress and b) stiffness test results of 
breaking stress and force of extruded filaments. 
Stiffness is another critical properties to determine the printability of the filaments. It is 
used to describe the mechanical properties of a structure, as the “load” needed to achieve a certain 
“deformation.”  
"Stiffness"= Load/Deformation 
There are varieties of possible configurations of the “load” (force, stress, arbitrary groups 
of forces, etc.) that acts on a structure. In addition, there is an infinite number of possible points in 
a structure, where deformation (displacement, angle, radius, curvature, etc.) can be measured [26]. 
A strong filament will require a high breaking force; therefore, stress (ratio of force to cross-
sectional area) was taken to represent the actual stiffness of a filament. Furthermore, in this study, 
the breaking stress was considered as “load,” and the blade move 0.6 mm after touching the 
filament was considered as “deformation.”  
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As shown in figure 21 b), the PLA plastic has excellent stiffness, and the extruded filaments 
were not as good as the reference material, which means they can be easily broken during the 
feeding process. As observed from the printing process, the HPC filaments were soft, and plastic 
deformation happened during the printing process, while the EC formulation shows very brittle 
and easily broken by the feeding gear. HPMC and HPMCAS showed proper stiffness, and there 
almost no plastic deformation or surface crack observed during the printing process. 
From the observation, if the filaments intend to be widely used for a variety of 3D printers, 
it better has adequate flexibility (breaking stress >635.5 g/mm2), toughness (breaking 
distance >0.61 mm), and stiffness (20758.3 g/mm2). Alternatively, the other option is to adjust the 
force of the feeding system, make sure the force to convey the filament is smaller than 400.7 g. 
2.3.4.3. Rheology characterization of the filaments  
Furthermore, the roughness and rheological properties of filaments can influence the 
printing process. High-melt viscosity can affect both extrusion and the 3D printing process. It can 
result in the production of filaments with rough surfaces, which can block the nozzle or disrupt 
extrusion during the printing process. As shown in figure 22a, APAP showed plasticizer effect 
during the extrusion process, which results in the attenuation of the viscosity of the system when 
adding 30 % w/w APAP. In general, higher viscosity resulting in a rough surface and hard to 
extrusion and print.  Here, drug-loaded EC N14 filaments have higher viscosity. However, the 
surface of this filament is smooth. Based on the observation and SEM pictures of each printed 
tablets, the HPMCAS tablets have fine appearance may due to the low viscosity of the formulation. 
Both HPMC tablets showed rough printing paths because of the relatively high viscosity compare 
to HPMCAS formulations. However, even though EC formulation has higher melt viscosity, the 
printed tablets still have a relatively fine appearance compare to the HPMC formulations. 
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Figure 22. a) frequency sweep of the raw materials and drug-loaded extrudates; b) temperature 
sweep of the milled printable filaments.  
2.3.5. 3D printing  
From the characterization of the physical-chemical properties of the filaments, the 
printability of different formulations can be predicted. As expected, HPMC might be the perfect 
choice for FDM based pharmaceutical 3D printing because it can be smoothly printed without any 
failure. For the HPMC K100M grades, it cannot be printed through the printer because of the larger 
molecular weights which resulting in the high melting viscosity. Both HPC filaments were too 
flexible and soft to be printed, it was observed that the filaments would be pushed aside by the 
feeding gear, and the filament was not stiff enough to push the molten materials out of the nozzle. 
Both HPMCAS HG and LG formulations are a little bit brittle and lack of flexibility, which results 
in the breaking during feed into the hot end by the feeding gear. Even though, HPMCAS filaments 
can occasionally be printed, with average six failures per 10 prints. EC filaments also showed very 
brittly and some times can be printed, with average five failure per 10 prints. However, once the 
tablets successfully printed, it will have the smooth and homogeneous surface.  
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The appearance of the tablets was primarily affected by rheology properties of the materials. 
The printed EC tablets showed very smooth and homogeneous surface compare to the other tablets. 
Conjugation and adhesion were observed from the HPMCAS tablets, which due to the high melting 
viscosity. The HPMC E5 tablets were showed proper appearance and smooth surface (figure 23).   
 
Figure 23. SEM pictures of the cross section of the 3D printed the tablets.  
All the printed tablets seem “wider” and “shorter” than the designed dimensions, which 
may occur due to the cooling and solidification of the materials. The cooling and solidification 
take longer time resulting in the growing pressure from the just printed layer to the previous 
unsolidified layer. So the bottom part was slightly wider, and the height of the tablets was shorter 
than the designed dimensions. So further optimization of the printing speed and cooling time need 
to be done to grantee the quality of the 3D printed tablets. The weight is different for each 
formulation of the printed tablets wares between 4.5%-7.2% w/w. The weight variation may 
predominate by the rheology properties as well. As shown in table 5, the better flowability turns 
gives smaller variation (4.73% for EC and 4.77% HPMC E5 tablets), and vice versa, the higher 
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melt viscosity gives more considerable variation (6.54% for K100M, 7.11% for HG and 7.08% for 
LG tablets). So further studies on optimizing the formulations will be needed for pharmaceutical 
dosage development. 
Table 5. Geometry study of the tablets. (n = 10, arithmetic mean±SD). 
 Diameter 
(mm) 
Thickness 
(mm) 
Weight 
(mg) 
Variation 
(w, %) 
Hardness 
(kp) 
Fail per 
10 prints 
HPMC E5 11.22±0.07 4.46±0.05 395.58±18.72 4.73 OV* 0 
HPMC K100M 10.51±0.24 4.22±0.21 377.91±24.73 6.54 OV* 8 
HPMCAS LG 10.33±0.28 4.40±0.22 366.93±26.12 7.11 32.8±5.6 6 
HPMCAS HG 10.91±0.30 4.29±0.19 352.04±24.94 7.08 32.2±5.3 6 
EC N14 10.47±0.16 4.42±0.05 354.19±16.92 4.77 23.8±6.5 5 
*OV=over the limit. 
2.3.6. In vitro drug release  
 
Figure 24. the in vitro drug release profiles of 3D printed tablets in SIF. 
Dissolution tests were conducted in US Pharmacopeia Simulated Intestinal FluidTS 
(without pancreatin) (pH 6.8), more representative of human small intestinal fluid. It is apparent 
that the dissolution profiles show different behaviors. Poorly water-soluble API can disperse or 
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dissolve into the polymer matrix and form a solid dispersion or solution via HME process because 
of mixing of molten drug and polymers[41]. As expected, all HPMC E5 tablets have faster drug 
release rate because the HPMC matrix can form hydrogel rapidly and release the drug. Show 80% 
release after 2 h and reach 100% drug release in 4 h. The drug release from the matrix while the 
polymer matrix was also dissolved as well, so finally the tablet was dissolved entirely after 4 h.  
AquaSolveTM HPMCAS LG and HG tablets showed similar drug release profiles, and LG 
grade has faster drug release rates due to the high contents of the succinic groups (14-18%) 
compare to the HG grades (4-8%). Both LG and HG tablets can release APAP over an extended 
period (51% and 45% drug release after 12 h, respectively). The HPMCAS matrix also interacts 
with the water and formed a hydrogel, but not like the HPMC matrix, the drug can release from 
the matrix, but the polymer just absorbs the water and which can not completely dissolve in 24 h. 
So the drug released rates were predominated by the swelling speed and the matrix itself. As we 
can see from the drug release profiles, the drug released from the HPMCAS matrix was more 
steady compared to the drug released from the HPMC matrix. So the HPMCAS matrix was the 
better choice for the controlled released dosage development. 
Aqualon EC is soluble in a wide variety of solvent but hardly soluble in water, which means 
the EC formulation may not cause erosion or swell in the dissolution media. The EC tablets just 
released 8.9% APAP at the end of the 24 h dissolution period. As mentioned in the previous 
discussion, most of the APAP has been dissolved or dispersed into the EC polymer matrix and 
formed a solid dispersion. So the polymer matrix stops the APAP release from the polymer matrix 
to the dissolution media, the drug released came from the undissolved APAP which was not 
entrapped in the polymer lattice or on the surface of the tablets. The tablets can not disintegrate as 
well, and APAP was hardly released from the matrix.  
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2.4. Conclusion 
In this work, a variety of polymers have been tried for the manufacturing of the drug-loaded 
and 3D printable filaments. APAP was miscible with them and can dramatically improve the 
extrudability of the polymers. Also, the physical and chemical characterization showed that APAP 
could dissolve or dispersed into the HPMC and HPMCAS matrix and form the amorphous solid 
dispersions, while it can only partially disperse into the EC and HPC matrix. The mechanical 
characterization on the extruded filament showed that the HPMC E5 grades are good for 3D 
printing because it has proper flexibility, toughness, and stiffness. Both HPC filaments were soft 
even cannot feed into the 3D printer. EC filaments were very brittle and easily broken by the feed 
gear, it can be printed but need to be taken care during the printing process. Both HPMCAS 
filaments can be printed but not as good as the HPMC filaments. As predicted, the printed HPMC 
tablets showed fast drug release profiles while HPMCAS tablets were in controlled drug release 
rates. Moreover, EC formulation may good for the extend drug release dosage forms because the 
drug release rate was meager compared the other formulations. All in all, in this work, we 
successfully manufactured the drug-loaded filaments utilizing the pharmaceutical HME process. 
In addition, we also characterized the physical and chemical properties of the filaments for 
screening the filaments suitable for FDM based 3D printing or not. HPMC was a better selection 
for the new 3D print dosage development. This work also demonstrated the possibility of 
combining HME and 3D print technology as a continuous process. In future, optimizing the 
formulations such as combined two or more polymer matrixes, adding plasticizer or anti-plasticizer 
would be good direction for the 3D printable filaments developments. 
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CHAPTER 3 
HYDROXYPROPYL METHYLCELLULOSE-BASED CONTROLLED RELEASE 
DOSAGE BY MELT EXTRUSION AND 3D PRINTING: STRUCTURE AND DRUG 
RELEASE CORRELATION 
3.1. Introduction 
Drug delivery systems (DDSs) are methods of administering active pharmaceutical 
ingredients (APIs) to achieve a therapeutic effect in humans or animals. They aim to ensure optimal 
drug distribution and absorption and improve efficacy and safety by controlling the rate, time, and 
target of drug release in the body [42]. Approaches for effective DDSs include controlled release 
formulations, in which the drug is released at a controlled rate over a set period of time and targeted 
delivery [44][43] in which the drug is only active in a targeted area of the body, such as in 
cancerous tissues [45][46]. Controlled release technologies can be broadly categorized into 
liposomal [47], electromechanical [48], and polymeric types [15]. The use of liposomes for 
controlled delivery has been widely studied, but in vivo instability and entrapment by the 
reticuloendothelial system are two major obstacles to be overcome [49]. The use of pumping 
devices to control the amount of drug released is in principle the most direct and sophisticated 
approach; however, osmotic pump systems are much more expensive and may be subject to dose 
dumping if the membrane breaks [50]. Polymeric controlled release systems, which use 
biodegradable, non-biodegradable, and soluble polymers as drug carriers, can be administered via 
parenteral, implantation, oral, insert, and transdermal routes [51]. Nowadays, polymeric oral-
controlled release technologies are considered economical and immediately applicable in drug 
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development, improving patients’ quality of life by reducing the inconvenience caused by the 
frequent dosing of conventional tablets [29]. Furthermore, the increased use of additive 
manufacturing, also known as 3D printing technology, provides an effective solution for individual, 
complex production of oral-controlled DDSs [52]. 3D printing is the layer-by-layer production of 
3D objects from digital designs [11]. Compared with developing new materials for drug delivery, 
the development of new material fabrication tools and protocols is more efficient and economical. 
3D printing technology provides an alternative means of engineering release profiles, by 
controlling the spatial distribution within a given polymer composition rather than creating a new 
host material [30]. 
Hot-melt extrusion (HME) is a manufacturing technique that, unlike traditional oral dosage 
manufacturing techniques, such as direct compression and tableting [5], generally involves the use 
of twin-rotor extruders that process water-soluble polymeric excipients, mixing them with APIs 
while molten to cause partial or total API dissolution, and pump the homogeneous mixture through 
a die to form an extrudate containing the API in a stable form [10]. 
HME has been used in the plastic and rubber industries since the 1930s. Pharmaceutical 
HME is currently being investigated by both industry and academia as a means to increase the 
release rate of poorly water-soluble APIs by melt-mixing them with hydrophilic, water-soluble 
polymers [8]. HME can help overcome poor API bioavailability, create new modified-release drug 
systems, and mask bitter tastes [53]. At the same time, an increasing body of literature exists on 
the production of controlled release dosages by melt-mixing readily water-soluble APIs with rate-
controlling polymers.[54] 
Compared to traditional pharmaceutical manufacturing processes, combining HME and 3D 
print technology as a continuous process highlights their respective advantages to 1) increase the 
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solubility and bioavailability of poorly water-soluble drugs; and 2) produce more complex 
structured dosages and personalized drug products. In addition, combining the technologies 
reduces the required downstream processing, making it more efficient and economical. The Food 
and Drug Administration (FDA) has recently encouraged the production of oral solid dosages that 
meet the increasing demands of oral drug delivery in terms of API bioavailability and drug release 
characteristics, in a continuous and controlled process [22]. 
The basic steps involved in continuous pharmaceutical HME/3D printing dosage 
production are 1) dosage design and conversion to a printer-readable format; 2) raw material 
preparation (powders, particulates, granules, pastes, etc.); 3) HME to produce filaments; 4) 
filament cooling; 5) 3D printing; and 6) removal and downstream processing (such as cooling, 
drying, and packing, etc.) In continuous pharmaceutical HME/3D printing, extrusion of the 3D 
printable filaments is a very important step, along with dissolving poorly water-soluble APIs into 
molten polymeric excipient and mixing, which improves the final dosage bioavailability[55]. 
The aim of this novel study was to couple fused deposition modeling (FDM) 3D printing 
with HME technology to print hydroxypropyl methylcellulose (HPMC)-based controlled release 
tablets with various structural designs and drug release profiles. 
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3.2. Material and methods 
3.2.1. Materials 
Acetaminophen (APAP; Spectrum Chemical, New Brunswick, NJ, USA) was selected as 
a model API. APAP is crystalline, and in the Biopharmaceutics Classification System is considered 
a borderline compound between class I (high permeability, high solubility) and class III (low 
permeability, high solubility), with a melting point of 169–170°C [56]. Benecel™ HPMC E5 was 
donated by Ashland Inc. (Covington, KY, USA). HPMC has been investigated for the preparation 
of oral drug delivery systems and is one of the most widely used hydrophilic matrix materials 
[57][58]. It can significantly affect the release kinetics of APAP due to its high swellability [59]. 
Once the tablets contact the dissolution media, the polymer chain will have relaxed with volume 
expansion, thus it diffuses into the matrix [60], then, the APAP diffuses out of the system [61]. 
HPMC E5 has an average molecular weight of 34,500 Da and normal viscosity of 4.0–6.0 mPa・
S. Soluplus® was donated by BASF (Ludwigshafen, Germany) and is a co-polymer of polyethylene 
glycol, polyvinyl acetate, and polyvinylcaprolactam-based graft with an amphiphilic chemical 
structure, particularly developed for solid dispersions, which acts as a polymeric solubilizer. Due 
to its functional groups, it can both solubilize poorly water-soluble APIs in aqueous media and act 
as a matrix polymer in solid dispersions[62]. All other reagents were either HPLC- or analytical-
grade. 
3.2.2. Methods 
3.2.2.1. Formulation 
APAP, Soluplus®, and HPMC E5 were combined at a weight ratio of 1:2:7 and tumble-
mixed on a MaxiblendTM (GlobePharma, New Brunswick, NJ, USA) at 25 rpm for 30 min, after 
filtration through a US #30 mesh screen to remove any aggregates that may have formed. 
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3.2.2.2. Hot melt extrusion (HME) 
The extruder used in this study was a co-rotating, twin screw extruder with 11 mm diameter 
screws, a length/diameter ratio of 40, and eight electrically-heated zones (Thermo Fisher Scientific, 
Waltham, MA, USA); feeding zone temperature was controlled by an external circulation heater. 
Physical mixtures were extruded at 160°C for all zones with a standard screw configuration at a 
screw speed of 50 rpm. A 2 mm-round die was used to extrude filaments for the 3D printer. A 
conveyor belt was used to cool and straighten the filaments for feeding into the 3D printer. 
3.2.2.3. Differential scanning calorimetry (DSC) 
A Diamond DSC system (PerkinElmer, Waltham, MA, US) was used to study drug 
crystallinity and characterize drug miscibility in the extrudates. Samples (2–5 mg) were 
hermetically sealed in an aluminum pan and heated from 40–200°C at a rate of 10°C/min. Ultra-
purified nitrogen was used as the purge gas at a flow rate of 50 mL/min in all DSC experiments. 
Data were collected and analyzed with Pyris software (PerkinElmer). 
3.2.2.4. Thermogravimetric analysis (TGA) 
During HME processing, a PerkinElmer Pyris 1 TGA calorimeter was used to determine 
the thermal stability of APAP and the polymers. The samples were placed in an open aluminum 
pan and heated from 30–300°C at a rate of 20°C/min. Ultra-purified nitrogen was used as the purge 
gas at a flow rate of 25 mL/min. Data were collected and analyzed using Pyris software, and 
percentage mass loss and/or onset temperatures were calculated. 
3.2.2.5. 3D printing  
The model tablets were designed using Microsoft 3D Builder (Microsoft, Redmond, WA, 
USA), sliced using CURA software (version 15.04; Ultimaker, Geldermalsen, The Netherlands), 
and then converted to .gcode files. Nine tablets were designed, with the same overall tablet 
dimensions (diameter, 10 mm; thickness, 4.5 mm), but with different outside shell thicknesses or 
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core fill densities (Figure 25). Tablets were fabricated from the extruded filaments using a 
commercial FDM-3D printer (Prusa i3 3D desktop printer, Prusa Research, Prague, Czech 
Republic) with an extruder, which had an E3D v6 HotEnd and a 0.4 mm nozzle. The best tablets 
were produced using standard resolution with the raft option activated, and an extrusion 
temperature of 200°C. Other settings used were as follows: bed temperature, 50°C; printing speed, 
50 mm/s; nozzle traveling speed, 50 mm/s; layer height, 0.10 mm. The dimensions and weights of 
the 3D printed (3DP) tablets were then measured. To determine the dissolution kinetics, empty 
tablets (1.6 mm and 0.4 mm outside shell) were also printed. 
 
Figure 25. 3D tablet designs with varied outside shell thicknesses and inner core fill densities. 
3.2.2.6. Assessment of tablet morphology 
A digital caliper (VWR®, PA, USA) was used to determine the diameters and thicknesses 
of the tablets, and cross-sectional images of the 3DP tablets were acquired using a JOEL JSM 
5610LV scanning electron microscopy (SEM) (JOEL, MA, USA).[63] 
3.2.2.7. Determination of tablet strength 
A standard tablet hardness tester (VK200; Agilent Technologies, Santa Clara, CA, USA) 
56 
 
with a maximum force of 35 kp was used to measure tablet hardness. Six tablets from each group 
were tested. 
3.2.2.8. In vitro drug release 
Drug release from different 3D structured tablets was determined using a United States 
Pharmacopeia (USP) dissolution apparatus II (Hanson SR8-plus™; Hanson Research, Chatsworth, 
CA, USA). Dissolution tests were conducted as per US Pharmacopeia standards using Simulated 
Intestinal FluidTS (without pancreatin, pH 6.8), which is representative of the small intestinal fluid 
of humans. Each experiment was carried out in triplicate using 900 mL of dissolution medium at 
37 ± 0.5°C for 24 h. The paddle speed was set at 50 rpm. Due to their porous internal structures, 
tablets #8 and 9 floated; therefore, sinkers were used to keep the tablets submerged in the 
dissolution vessel. Samples were analyzed at 0.5, 1, 2, 4, 5, 6, 8, 10, 12, and 24 h. The amount of 
released APAP was determined by HPLC (Waters Corp., Milford, MA, USA) at 246 nm and 
analyzed using Empower software (version 2, Waters Corp.). 
3.2.2.9 Dissolution kinetics studies  
One of the main objectives was to combine the HME and 3D print to produce zero-order 
release dosages through the optimization of the 3D structure. In order to investigate the dissolution 
kinetics, the dissolution data were fitted to several mathematic models, including the Higuchi, 
Ritger-Peppes, Peppes-Sahlin, and zero-order models, and a correlation coefficient (R2) was used 
to evaluate the accuracy of the individual models. 
3.3. Results and discussion 
3.3.1. Preliminary study of raw materials 
TGA can provide information about decomposition or drug degradation [64]. According to 
the TGA results, mass loss of APAP and the physical mixtures emerged at temperatures above 
350°C, indicating that the drug and polymer matrix would not degrade during melting extrusion at 
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160°C and 3D printing at 200°C. Extruded filaments were fed into the 3D printer HotEnd by 
feeding gears at 14 ºC, and then melted in the HotEnd hose, avoiding drug decomposition or 
degradation during the printing process. Though a standard screw configuration with 3 different 
mixing zones was utilized during HME processing, which would have a high shear force resulting 
in drug decomposition or degradation, drug content result was confirmed with final in vitro drug 
release studies. 
DSC is a thermoanalytical technique to detect phase transitions in samples, with the 
premise that when the sample undergoes a phase transition, more heat will be required than that 
required by a reference sample.[7] The APAP DSC curve exhibited a peak at 172°C. A heat-cool-
heat method was utilized for DSC analysis of the physical mixture. As expected, the physical 
mixture showed an obvious peak at approximately 170°C during the first heating process and no 
peak during the second heating process. This result indicated that APAP can disperse or dissolve 
into the molten polymer matrix during HME processing, forming an amorphous solid dispersion. 
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3.3.2. Tablet morphology study 
3.3.2.1. 3D structure 
 
Figure 26. 3D structure of tablet #5, with a 0.4 mm shell and 80% inner fill. 
All tablets were successfully printed with designed 3D structures. Due to space limitations, 
one sample (tablet #5, with a 0.4 mm shell and 80% inner fill) is shown in Figure 26. Tablets were 
broken and split apart rather than cut, as the blade would destroy the inner 3D structures. Figure 
26a shows the clearly layered structure of the 0.4 mm shell and inner fill. Figure 26b shows a cross 
section of porous structure of the inner fill. Figure 26c demonstrates the layered structure of the 
tablet shell. 
As shown in Figure 27a, in tablets without an outside shell, the porous inner fill structure 
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is in direct contact with the medium, while in the 0.4 mm and 1.6 mm shell tablets, the outside 
shell acts as a barrier for the inner porous structure, preventing the core from direct contact with 
the medium. Due to the erosion and swelling effects of HPMC and Soluplus®, the tablets slowly 
dissolve in dissolution medium rather than disintegrate[65]; therefore, tablets with 16 mm shell 
thickness should dissolve not only much slower but also at more constant rates than the other 
tablets 
As shown in figure 27b, tablets with 100% core fill density have a very solid structure with 
limited surface area, and were expected to have the slowest drug release rates. Tablets with 80% 
and 20% fill density exhibited porous structures with larger surface areas. However, low inner fill 
density will also affect the hardness of the tablets. 
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Figure 27. a) 3D structures of tablets printed with no shell or with shells of 0.4 and 1.6 mm 
thickness; b) Tablets with 100, 80, and 20% inner core fill density. 
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3.3.2.2. Tablet morphology 
Images from the tablet morphology study and SEM analyses revealed that the 3DP tablets 
had smooth surfaces and a tight structure. Generally, tablets with a higher core fill density or 
thicker shells had higher density and hardness than tablets with lower core fill and thinner shells 
(Table 6). The hardness of tablets designed with 100% fill exceeded the detection limit of the 
hardness tester, and tablets with 80% fill were harder than tablets with 20% fill. The outside shell 
thickness also affected hardness, as tablet #9, with a 1.6 mm shell, was much harder than other 
tablets with same fill density. The hardness test can only measure stress towards the tablets; 
however, in the vertical direction, the structure was loose and easy to split, even when the hardness 
exceeded the limit of detection. 
The volume of each cylindrical tablet was calculated as follows:  
 
𝑉 =
𝜋𝐷2
4
∗ ℎ Eq 3 
where D and h are the diameter and thickness of the tablets, respectively. Thus, the 
theoretical density of a tablet was calculated according to the following equation: 
 
𝜌 =
𝑚
𝑉
=
4𝑚
𝜋𝐷2 ∗ ℎ
 Eq 4 
where m is the weight of the tablet. The density of the HME-generated filaments was 
calculated using the same equation. As shown in Table 6 the theoretical density of 3DP tablets was 
much higher than that of unprinted filaments. In addition, tablets with high hardness and density 
values are expected to have delayed dissolution and slow drug release after administration. In the 
geometric study, the tablets had only small variations in weight (the largest is T7, at ~7%) and 
dimensions, which demonstrate the good reproducibility of the 3D printing process. Based on the 
weight of the tablets and shell without inner fill, the 0.4 mm shell was approximately 47.99% of 
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the overall weight of T2, 53.04% of T5, and 79.31% of T8. The weight of the 1.6 mm shell was 
approximately 80.09% of the overall weight of T3, 82.42% of T6, and 96.77% of T9. 
Table 6. Geometric characteristics of the 3D printed tablets 
*OV= over detection limit 
3.3.2.3. Porosity study of the tablets 
The SEM images (not shown) indicated that the extrudate filament was robust, the structure 
was not porous, and the materials were extruded from the nozzle of the printer, so all the porosity 
is generated from the tablet 3D structure design. The porosity of the 3D printed tablets can be 
expressed by using the following equation [66]:  
 
𝑃 =
𝑉𝑣𝑜𝑖𝑑
𝑉𝑔𝑒𝑜𝑚𝑒𝑡𝑟𝑖𝑐
 Eq 5 
where 𝑉𝑣𝑜𝑖𝑑 is the total volume of the empty space inside the tablets and 𝑉𝑔𝑒𝑜𝑚𝑒𝑡𝑟𝑖𝑐 is the volume 
of the tablets as a whole object. As shown in Figure 3, 100% filled tablets can be considered as 
solid with no porous structure and the porosity of tablets #4 and #7 can be considered as the 
designed fill density. Based on the geometric measurements and tablet designs, the calculated 
 Shell  
(mm) 
Fill  
% 
Diameter 
(mm) 
Thickness  
(mm) 
Weight 
(mg) 
Density 
(mg/mm3) 
Porosity 
(%) 
Hardness 
(kp) 
T1 0 100 11.22±0.07 4.46±0.05 435.45±15.21 0.988 0 OV* 
T2 0.4 100 10.51±0.24 4.22±0.21 377.91±24.73 1.030 0 OV* 
T3 1.6 100 10.33±0.28 4.40±0.22 366.93±26.12 0.992 0 OV* 
T4 0 80 10.91±0.30 4.29±0.19 352.04±24.94 0.877 20 OV* 
T5 0.4 80 10.47±0.16 4.42±0.05 354.19±16.92 0.931 13.97 32.8±5.6 
T6 1.6 80 10.36±0.19 4.47±0.02 395.58±18.72 1.050 2.71 32.2±5.3 
T7 0 20 10.28±0.18 4.35±0.16 176.51±12.65 0.489 80 2.7±1.4 
T8 0.4 20 10.21±0.16 4.48±0.05 197.19±11.62 0.538 55.82 5.3±4.2 
T9 1.6 20 10.39±0.25 4.41±0.22 319.34±10.46 0.854 10.51 23.8±6.5 
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porosity of the tablets is listed in Table 6. Tablets #7 and #8 showed faster release rates than the 
other tablets with the same shell, because of both the thin shell and porous structure. For the other 
tablets, owing to the robust shell structure and swelling of the matrix, the inner core porous 
structure had a limited impact on the dissolution kinetics.  
3.3.3. In vitro drug release 
3.3.3.1. Drug release profiles  
 
Figure 28. In vitro drug release profiles of tablets (T) with no shells and with shells of 0.4 and 1.6 
mm thickness. 
As shown in Figure 28, tablets with 1.6 mm shells had extended drug release rates due to 
the 3D structure of the thicker shell, while tablets without shells exhibited fast release profiles, 
because the inner structures were loose and direct contact with the dissolution media. The 0.4 mm 
shell was totally dissolved within 4 h, which was confirmed by drug release studies, showing 100% 
drug release in 4 h. Based on the tablet geometry study, the calculated weight ratios of 0.4 mm 
shells were 47.99%, 53.04%, and 79.31% for T2, T5, and T8, respectively, and the percentage of 
drug released after 4 h was 52.91%, 54.27%, and 79.41%, respectively, suggesting that the inner 
core releases the drug after the shell is dissolved. Tablets with 1.6 mm shells released APAP over 
a longer period, with 71%, 79%, and 66% of drug released after 8 h from T6, T7, and T8, 
respectively. In the 100% fill tablets, the drug release rate from T1, which had no shell, was higher 
No shell 0.4mm shell 1.6mm shell
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than those for T2 and T3, which indicated that the inner core with 100% fill has a looser structure 
than the shell. T7 (20% inner fill, no shell) exhibited 74% drug release within 0.5 h and 85% drug 
release in 1 h, and all tablets without shells had released at least 70% of the drug within 4 h. The 
linear regression of no shell tablets was lower than 0.88. As expected, the released rate was 100%< 
80%< 20%. 
The drug dissolution rates of tablets with each designed 3D structure were evaluated. 
Poorly water-soluble APIs can disperse or dissolve in polymer matrices to form solid dispersions 
or solutions during the HME process [28]. As mentioned in the DSC results, APAP was completely 
dissolved into the polymer matrix, forming an amorphous solid dispersion. The observed 
dissolution and drug release rates from the HPMC based matrix were influenced by the 3D 
geometric structure and composition, and the following phenomena were observed in the in vitro 
drug release study: 
1) Once the tablets contacted the dissolution media, a steep concentration gradient formed at 
the media/tablet interface. Here, water acted as a plasticizer and reduced the glass transition 
temperature (Tg) of the system. Once the system reached the Tg during the in vitro study, 
the matrix transformed to hydrogel [59]. 
2) The HPMC-based matrix swelled and formed hydrogel while the media were penetrating, 
which changed the drug concentration at the media/tablet interface. Matrix imbibition of 
the media through the tight shell structure was the most important rate-controlling step 
during the dissolution study. The media took longer to penetrate through the thicker shell 
than through the thinner shell and inner core. 
3) The concentration gradients led the APAP to diffuse from the media/tablet interface to the 
hydrogel, and thus into the dissolution media. 
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4) The more porous lower fill density was less restrictive for drug diffusion upon drug 
depletion, meaning that APAP dissolved and diffused more rapidly from the HPMC chain. 
Conversely, due to the tight structure of the high fill density and thicker shell, the APAP 
was slowly released from the matrix. 
All groups of tablets achieved ~100% drug release within 24 h, confirming that no API or 
excipient degradation occurred during the HME or 3D printing processes. There are various 
mathematical kinetic models that can be applied to describe in vitro drug release kinetics, such as 
Higuchi [67], Ritger-Peppas [68], Sahlin-Peppas [69], first order, and zero order, which help 
researchers understand release mechanisms and optimize formulations. Drug release can be 
considered either Fickian or non-Fickian diffusion. In Fickian diffusion, the drug release rate is 
independent of the drug concentration in the matrix [70]. 
3.3.3.2. Dissolution kinetic studies 
Higuchi equation is developed by Higuchi in 1961, which is one of the most famous and 
most often used mathematical model to describe the drug release rate from the matrix systems [71]. 
The original equation of Higuchi model is: 
 𝑀𝑡
𝐴
= √𝐷(2 ∗ 𝐶0 − 𝐶𝑠) ∗ 𝐶𝑠 ∗ 𝑡 Eq 6 
here 𝑀𝑡 is the accumulative drug released in time 𝑡; 𝐴 is the overall contact surface of the 
matrix to the medium; 𝐷 is the drug diffusivity in the polymer; 𝐶0 and 𝐶𝑠 are the drug concertation 
at beginning time and solubility in the polymer. Such equation can be simplified as following: 
 𝑀𝑡
𝑀∞
= 𝑘𝐻 ∗ 𝑡
1/2 Eq 7 
where the cumulative amount of the drug in the system, 𝑘𝐻 is a constant contains the 
information of the structure and geometry of the matrix [72]. The Higuchi model initially only 
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applicable for planer systems and then was modified and extended by researchers for variety of 
matrix [73][74][75]. The accumulative released drug is proportional to the square root of time. 
Researchers point out the original equation can only be used for “ideal” controlled released matrix 
because it was derived under pseudo-steady states and it validity is dependent upon the following 
assumptions [76]:   
i. The initial drug concentration is much higher than the drug solubility. 
ii. Drug diffusion is one-dimensional, making edge effects negligible. 
iii. The suspended drug micro- or nanoparticles are much smaller than the thickness 
of the system. 
iv. Swelling or dissolution of the polymer carrier can be neglected. 
v. The drug diffusion coefficient is constant. 
vi. Perfect sink conditions prevail and are maintained. 
Higuchi model was not applicable for this work because the 3D printed matrix may 
diffusion multidimensional and the swelling of the matrix is unneglectable, the initial drug 
concentration of in vitro study can`t meet the assumptions listed above as well. 
We applied the data from the in vitro drug release study to the Ritger-Peppas model (also 
as known as “power law”), a simple model that exponentially relates the drug release to the 
fractional release of the drug, developed by Peppas et al. in 1983. The Ritger-Peppas model can 
be described as the following: 
 𝑀𝑡
𝑀∞
= 𝑘 ∗ 𝑡𝑛 Eq 8 
where 𝑀𝑡 is the cumulative amount of drug released at time t, 𝑀∞ is the total amount of 
drug, 𝑘 is a constant incorporating structural and geometric characteristics of the device, 𝑡 is the 
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time at which drug release is calculated or measured, and 𝑛 is the release exponent, indicative of 
the mechanism of drug release [77]. 
Table 7. In vitro dissolution parameters of the 3D printed tablets 
 Ritger-Peppas model Linear model Peppas-Sahlin model 
Exponent, n R2 Slope, k R2 k1 k2 m R
2 
T1 0.59 0.9872 7.14 0.8881 0.29014 -0.0277 0.8509 0.9975 
T2 0.69 0.9924 5.28 0.9254 0.20396 -0.0145 0.8348 0.9956 
T3 0.78 0.9808 5.46 0.9790 0.06398 0.0732 0.4685 0.9861 
T4 0.71 0.9968 6.02 0.8472 0.18201 0.0746 0.5061 0.9949 
T5 0.64 0.9973 4.97 0.9399 0.18909 0.0074 0.6001 0.9968 
T6 0.82 0.9968 5.82 0.9585 0.11352 0.0314 0.6168 0.9979 
T7 0.10 0.8971 1.41 0.2995 - - - - 
T8 0.67 0.9801 2.36 0.5606 - - - - 
T9 0.79 0.9900 5.00 0.9271 0.12184 0.0437 0.5939 0.9869 
*T7, T8 parameters were not calculated because their released rate too fast (over 60% in 2 h). 
Ritger and Peppas’s work shows this model has good ability for fitting before reaching 
approximately 60% total amount of drug release, and the equation has two distinct physical 
realistic meanings in the special cases of 0.45 (Fickian diffusion) and 0.89 (Case II transport). The 
Case II transport mechanism is a very near approximation of a normal Fickian diffusion process. 
If 0.45< n< 0.89, it indicates the superposition of both phenomena (anomalous transport). These 
two extreme values for the exponent n are only valid for cylinder geometry [68]. 
All the calculated data are listed in Table 7. Though the shape were cylindrical, the tablets 
has different density along the axial direction from the core due to the specific 3D structure design, 
and T3 (n=0.78, R2=09808), T6 (n=0.82, R2=0.9968), and T9 (n=0.79, R2=0.9900) can be 
considered Case II transport, which can be defined to approximate Fickian diffusion. The drug 
release rate from HPMC-based matrix with a shell design can be dominated by the swelling 
kinetics of the polymer, resulting in Case II transport. For T2, n=0.10, indicating Fickian diffusion, 
but the tablet dissolved too quickly, with 74% of drug released by the first sample collection point 
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at 0.5 h, and R2=0.8971 indicates that there was limited accuracy when applying the model to T2. 
For other tablets, the exponent 𝑛 varied from 0.59–0.71, indicating that both the swelling and 
diffusion kinetics controlled the drug release rate from the matrix. Peppas and Sahlin also 
developed a model to analyze anomalous transportation: 
 𝑀𝑡
𝑀∞
= 𝑘1 ∗ 𝑡
𝑚 + 𝑘2 ∗ 𝑡
2𝑚 Eq 9 
where 𝑘1 , 𝑘2 , and 𝑚 are constants. The first term on the right-hand side represents the 
Fickian diffusional contribution, whereas the second term the Case II swelling contribution. The 
coefficient 𝑚 is the purely Fickian diffusion exponent which has same meaning with the 𝑛 in 
Ritger-Peppas model. The percentage of drug released due to the Fickian mechanism, 𝐹 , is 
calculated as: 
 
𝐹 =
1
1 +
𝑘2
𝑘1
𝑡𝑚
 
Eq 10 
The ratio of both contributions can be calculated as follows: 
 𝑅
𝐹
=
𝑘2 ∗ 𝑡
𝑚
𝑘1
 Eq 11 
Such equations were applied to investigate the effect of the differently designed 3D 
structures on drug release; however, significant effects on the resulting R/F-ratios were found with 
the investigated 9 different tablets and shells (Table 7). Here the Fickian contribution can be 
expressed as a function of 𝑡𝑚, then the relaxational contribution can be expressed as a function of 
𝑡2𝑚 . Compared with the 𝑛  in equation 5 and 𝑚  in equation 6, 𝑚 ≠ 𝑛 , thus the relaxational 
mechanism is not negligible [69]. For tablets T1 and T2, though the R2 values were good, the 𝑘2 
was negative when applying the Peppas-Sahlin model, making the data nonsensical and indicating 
that the drug releasing mechanism were anomalous transport. For tablets T7 and T8, the drug 
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release reached 60% in 2 h, which lacking data for calculating the 𝑘1, 𝑘2, and 𝑚. It is difficult to 
determine the importance of the Fickian or Case II mechanisms without using equations 7 and 8. 
Figure 29 shows that along with the time or the drug released from the matrix, the Fickian diffusion 
domination decrease for the first 6 h or 60% of drug released from tablet T5, and the tablet T3 R/F 
curve indicating that the drug release was dominated by the swelling mechanism. Tablets T4, T6, 
and T9 were predominated by Fickian diffusion then the swelling mechanism. In this study, the 
domination of the diffusion mechanism was decrease along with the time or the dissolution of the 
matrix. Both the diffusion and swelling mechanism indicating the constant and steady drug release 
rate. Summarize the result of Ritger-Peppas and Peppas-Sahlin model, tablets T3, T5, T6, and T9 
can be a proper candidate for zero order drug release. 
 
Figure 29. Swelling contribution, R to diffusion contribution, F ratio from tablets #3, 4, 5, 6, and 
9. 
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3.3.3.3. Zero order drug release 
Zero order release, in which the drug release rate is constant over a period of time, is the 
ultimate goal of all controlled release DDSs. The equation for zero-order release is as follows: 
 𝑀𝑡 = 𝑀0 + 𝑘 ∗ 𝑡 Eq 12 
where 𝑴𝒕 is the cumulative amount of drug released at time t, 𝑴𝟎 is the initial amount of 
drug, 𝒌 is the release kinetic constant, and 𝒕 is the time at which the drug release is calculated or 
measured. As all the tablets reached 80% drug release within 10 h, linear fitting of in vitro drug 
release data from all 9 tablet types are listed in Table 7. Due to the tight structure of the shell, the 
1.6 mm shell was totally dissolved within 24 h, and the drug release from the 1.6 mm shell (linear 
regression R2=0.9950), T3 (linear regression R2=0.9790), T6 (linear regression R2=0.9585), and 
T9 (linear regression R2=0.9271) was steady and constant (Figure 30), meaning that the tight 
structure of the shell resulted in nicely controlled (zero order) drug release rates. T4 (linear 
regression R2=0.8472) was almost zero order released, however when plot the first 6 h release data, 
that the T4 (linear regression R2=0.9966) and can be considered as zero order release, which 
confirmed the diffusion mechanism and swelling mechanism dominated the T4 contributes to the 
constant and steady 60% drug release. The linear fitting results were consistent with the fitting of 
the Ritger-Peppas and Peppas-Sahlin models, in which drug release from T3, T5, T6, and T9 was 
constant and steady. 
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Figure 30. Linear fitting of drug release from tablets #3, 5, 6, and 9 over 10 h. 
3.4. Conclusions 
In this study, we successfully fabricated solid-dispersion filaments with the API dissolved 
in a polymer matrix via HME technology. Extruded filaments prepared based on HPMC were 
printed with optimized 3D printing parameters, producing controlled release tablets with different 
3D structures. Based on Ritger-Peppas model fitting, drug release from HPMC-based matrix 
tablets T3, T6, and T9 may be considered Case II transportation diffusion, indicating that the rate 
of drug release is independent of time and concentration. Based on the Peppas-Sahlin model, T3, 
T4, T5, T6, and T9 were dominated by either diffusion or swelling mechanisms. T3, T6, and T9 
also had constant and steady drug release rates by linear fitting, confirming that the diffusion model 
can be considered sustained (zero order) release. In other words, compared to changing the 
formulation, polymer, or further processes, such as coating, 3D structure design is effective and 
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efficient for optimizing controlled drug release rates. In this work, the thick and tight outside shell 
structure act as a “barrier” during the in vitro drug release study, which contributes to the slow 
forming hydrogel and constant control of the drug release rate from the HPMC based matrix. Even 
though the inner fill tablet is 100% (T1), it cannot perform as well as the outside shell tablets (T3, 
T6, and T9). This study clearly demonstrates that coupling FDM-based 3D printing with HME 
offers a novel, economical, and efficient method for manufacturing complex, personalized dosage 
forms and better controlled release profiles dosages that can be prepared as required for individuals. 
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CHAPTER 4 
DEVELOPMENT OF CONTROLLED RELEASE ORAL DOSAGES WITH CORE-
SHELL STRUCTURE USING 3D PRINTING TECHNOLOGIES 
4.1. Introduction 
For a long time, drugs have been used to treat disease and improve health. Drug delivery 
systems (DDSs) refers to a method or process to achieve a therapeutic effect by transporting active 
pharmaceutical ingredients (APIs) in humans or animals body [42]. An effective DDS can be 
described as the API is released in a controlled rate over a period of time [78]. Targeted delivery 
can be also defined as the controlled release formulation where the drug is active in the specific 
target of the body such as, in cancerous tissues[45][46]. There are serval approaches can be used 
to achieve the controlled release such as polymeric matrix [66], electromechanical delivery [48], 
and polymeric matrix[47]. The two major issues for Liposome-based controlled formulation are 
poor long term in vivo stability and reticuloendothelial  system entrapment [49]. Using  of pumping 
devices for is the most sophisticated but extremely expensive approach controlled drug released. 
In addition, the membrane breaking of the osmotic pump system may subject to dose dumping 
[50].   
Oral drug administration has been developed for a long time  and proved is the most 
acceptable route, which is cost-friendly and easily accessed[79], however, there still the inherent 
limitations exist. As shown in figure 31, general single oral dose administration will take effects 
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slowly and just effective for a short period of time. In order to extend the therapeutic time, multiple 
dose can be given which inevitably cause the patient compliance [80]. Recently, polymeric oral-
controlled release technologies have gained a lot interest from both industrial and academic area 
because of the potential to improve patients’ quality of life (QOL) by reducing the inconvenience 
of frequent dosing in an economical and immediately approach [29]. The polymeric controlled 
release utilize hydrophilic, amphiphilic, or hydrophobic polymers (biodegradable, or non-
biodegradable) as drug-carriers, in which the APIs entrapped in the matrix and the polymer matrix 
controls the drug release rates[51]. Hot melt extrusion (HME) technologies have been developed 
and applied in pharmaceutical manufacturing for 2 decades and might be optimal for preparation 
of the polymeric formulations [5]. It mostly using twin-rotor extruders for the processing of soluble 
polymeric excipients and poor soluble APIs, mixing them while molten, thus, the APIs partially 
or totally dissolved into the polymer matrix and formed amorphous solid dispersions with 
improved bioavailability and stability [10]. However, due to the uniformity of the polymeric oral-
controlled release dosages, the drug release kinetics from the polymer matrix is slow.  
In addition, an significant issue researchers has to face during optimization of the oral 
administration is the individual variation, because of the patients has different races, genders, ages, 
pharmacogenetics, and pharmacokinetic characteristics and so on. Developing new molecular 
entity (NME) is complex, expensive, and time-consuming [81][82][83], so optimizing the 
currently available drugs to improve their bioavailability, or therapeutic effect could be effective 
and economical solutions [84][85][86]. Increasingly rising additive manufacturing (AM), also as 
known as 3D printing technology, is an optimal solution because it provides an effective solution 
for individual, complex consumption with the assistance of the computational design for oral-
controlled DDSs [87][88]. 3D printing is the layer-by-layer production of 3D objects from digital 
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designs[11], it also allows engineering release profiles by control of spatial distribution within a 
given polymer composition rather than creating a new host material [89]. 
 
Figure 31. Optimization of oral drug administration via HME/3D printing technologies. 
Compared to the traditional pharmaceutical products manufacturing process, combine 
HME and 3D print technology together will highlight each respective advantages: 1) increase the 
poorly water soluble drugs solubility and bioavailability; 2) produce more complex structured 
dosages and personalized drug products.  
Based on the advantages offered by coupling 2 technologies, the aim of this study was to 
couple fused deposition modeling (FDM) 3D printing with hot melt extrusion (HME) technology 
to enable Additive Manufacturing (AM) to print a core-shell structured controlled release tablets 
with dual mechanism drug release performance in the USP SIF media. A series of physical 
76 
 
chemical evaluation of the tablets as well as the comparation between direct compressed and 3D 
printed tablets were also conducted in this study. 
4.2. Material and methods 
4.2.1. Materials  
Acetaminophen (APAP) (Spectrum Chemical, New Brunswick, NJ, USA), a typical drug 
used to treat pain and fever, is selected as the model API. APAP is a crystalline and considered a 
borderline compound between Class I Biopharmaceutics Classification System (BCS) drug (high 
permeability, high solubility) and class III, with a melting point around 170-172°C [56].  
Benecel™ HPMC K4M (donated by Ashland Inc, Covington, KY, USA) with weight 
average molecular weight  ≃34,500 and melt viscosity ≃ 8.43×104 Pa・S at 160 C and 1 rad/s, is 
used as the shell matrix. It is one of the most widely used hydrophilic matrix material which has 
been investigated for the preparation of oral drug delivery systems[58]. The APAP release 
mechanisms and kinetics from the HPMC based matrix has been studied [59]. The high 
swellability allows the polymer chain relaxed with volume expansion when the matrix contacts 
with dissolution media, thus, the APAP diffuses out of the system[60].  
AquosolveTM HPMCAS HG (donated by Ashland Inc, Covington, KY, USA) weight 
average molecular weight  ≃18,000 and melt viscosity ≃ 4.62×104 Pa・S at 160 C and 1 rad/s, is 
selected as the core matrix. It is insoluble in stomach but will swell and dissolve rapidly in upper 
intestine, which commonly used as a solid-dispersion carrier to improve the poorly soluble API 
bioavailability[90]. All other reagents were either HPLC- or analytical-grade.  
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Figure 32. the chemical structure of the API and polymer matrix. 
4.2.2. Methods 
4.2.2.1. Formulation  
 
Figure 33. the 3D structure of porous fast release shell and condense extend release core. 
The overall tablets contains two parts, the porous fast release shell and condense extended 
release cores (figure 33). For the shell, 30% w/w drug were mixed with 70% HPMC K4M, while 
the core was 30% drug with 70% HPMCAS HG. The physical mixture (API+polymer) was 
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tumble-mixed using MaxiblendTM (GlobePharma, New Brunswick, NJ, USA) at 25 RPM for 30 
min, after passing through a US#30 mesh screen to remove any aggregates that may have formed. 
4.2.2.2. Preparation of the filaments  
A co-rotating, twin screw extruder with 11 mm diameter screws, L/D of 40, and eight 
electrically-heated zones (Thermo Fisher Scientific, Waltham, MA, USA) was used in this work; 
feeding zone temperature was controlled by an external circulation heater. Physical mixtures were 
extruded at 160°C for all zones with a standard screw configuration at screw speed 50 RPM. The 
molten materials was extrude through a 2 mm round shape die with an in -line NIR probe inserted 
as the PAT to monitoring the quality and homogeneity of the filaments, and a conveyor belt was 
used to cool and straighten the filaments to feed into the 3D printer. Polymer matrix without drug 
loading were also extruded at 200 C to evaluate the polymer-API interaction during the extrusion 
process.  
4.2.2.4. Differential scanning calorimetry (DSC) 
A TA DSC25 system (TA Instruments, New Castel, DE, USA) was used to study drug 
crystallinity and characterize drug miscibility with the extrudates. 8-10 mg of sample was 
hermetically sealed in an aluminum pan and heated from 25 to 200°C at a rate of 10°C/min. Ultra-
purified nitrogen was used as the purge gas at a flow rate of 50 mL/min in all the DSC experiments. 
Data were collected and analyzed with Trios software (TA).  
4.2.2.5. Thermogravimetric analysis (TGA) 
TGA was performed by using a PerkinElmer Pyris 1 TGA calorimeter to determine the 
thermal stability of APAP and the polymers during the HME processing. The samples were placed 
in an open aluminum pan and heated from 30 to 300 °C at a rate of 20 °C/min. Ultra-purified 
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nitrogen was used as the purge gas at a flow rate of 25 mL/min. Data were collected and analyzed 
using the Pyris software. Percentage mass loss and/or onset temperatures were then calculated. 
4.2.2.6. 3D printing  
The model tablets were designed using Microsoft 3D Builder (Microsoft, Redmond, WA, 
USA) and sliced by CURA software (version 15.04; Ultimaker, Geldermalsen, The Netherlands) 
then convert to .gcode file. Tablets were not only prepared using different polymer matrix for core 
and shell, but also designed to have a gradually decreasing internal density gradient which the core 
is 80% fill density and the shell is 50% fill density. Tablets were fabricated with the extruded 
filaments using a commercial FDM-3D printer (Prusa i3 3D desktop printer, Prusa Research, 
Prague, Czech Republic) with an extruder, which had an E3D V6 hot end and a 0.4-mm nozzle. 
The following printer settings were found to produce the best tablets: a standard resolution with 
the raft option activated and an extrusion temperature of 200°C. The other settings used were as 
follows: bed temperature, 50°C; printing speed, 50 mm/s; nozzle traveling speed, 50 mm/s; layer 
height, 0.10 mm. The dimensions and weights of the 3DP tablets were then measured. The printed 
shell and core were manually assembled as the core-shell structured tablets. 
4.2.2.7. Assessment of tablet morphology 
A VWR® digital caliper (VWR®, PA, U.S.) was used to determine the diameters and 
thicknesses of the tablets. Cross-sectional images of the 3DP tablets, and direct compressed 
extrudate tablets were taken using a JOEL JSM 5610LV scanning electronic microscopy (SEM). 
4.2.2.9. In vitro drug release study  
Drug release from the core-shell structured tablets, shell only, core only, and direct 
compressed extrudates tablets was determined using a United States Pharmacopeia (USP)-II 
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dissolution apparatus (Hanson SR8-plus™; Hanson Research, Chatsworth, CA, USA). Dissolution 
tests were conducted as per the US Pharmacopeial standards using Simulated Intestinal Fluid TS 
(without pancreatin) (pH 6.8), which is representative of the small intestinal fluid of humans. Each 
experiment was carried out in triplicate using 900 mL of the dissolution medium at 37 ± 0.5°C for 
24 h. The paddle speed was set at 50 rpm. Samples were taken at 5, 10, 15, 30, 60, 120, 180, 240, 
300, 360, and 420 min for analysis. The amount of released APAP was determined by HPLC 
(Waters Corp., Milford, MA, USA) at 246 nm and analyzed using Empower software (version 2, 
Waters Corp.) 
4.3. Results and discussions 
4.3.1. Thermal analysis 
 
Figure 34. the TGA graph of the raw materials: APAP, HPMC K4M, and HPMCAS HG. 
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Thermogravimetric analysis (TGA) is a measurement indicating the change in the physical 
properties and chemical properties of a material as the temperature (equal heating rate) or time 
(loss of isothermal and/or mass conservation) increases[91]. In this study, the TGA graph will 
show the moisture contents and the degradation of the raw materials. 1st derivative was plotted to 
show change of the thermal curves. As shown in figure 34, APAP and HPMCAS HG showed no 
moisture or crystalline water in the matrix, and they all have one degradation steps when heating 
above 350 °C. The HPMC K4M curve showed a 5% weight loss before reaches 100 °C, which 
indicating the water contents in the polymer. In addition, the torque was not high (2.88-4.32 Nm) 
during the extrusion process, which indicating there not much mechanical energy added into the 
extrusion process. So the extrusion process should not cause the degradation of the materials. The 
in vitro drug release study also showed cross verified there no degradation happened during the 
HME and 3D printing process. 
 
Figure 35. the DSC graph of the APAP, physical mixed (PM) formulations, and extruded (EXT) 
formulations. 
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Differential scanning calorimetry (DSC) is a thermal analysis technique that uses a 
compensator to measure the heating rate and temperature required to bring a sample and reference 
to the same temperature [92]. As the temperature rises, the crystallized structure begins to melt 
and the compensator measures the phase change necessary to increase the heat flow to overcome 
the melting, so as to maintain the consistent temperature, which results in an endothermic peak 
appears on the DSC curve [93]. As shown in figure 35, APAP showed a obvious melting peak 
around 172 °C, while physical mixtures showed a attenuated enthalpy around 150 °C and 160 °C, 
which indicating the APAP can be dissolve into the molten polymer matrix. The extrudates showed 
no peaks at all because with the help from the extrusion process, the crystalline API all dispersed 
or dissolved into the molten polymer matrix form amorphous solid dispersions. The polarized light 
hot stage microscopy can also confirm the formation of the ASDs, as shown in figure 36, APAP 
crystal can be clearly seen in the microscope, while heat to 160 °C, the polymer matrix melt and 
the API starts to dissolve in to the polymer matrix. As heat to 180 °C the APAP crystal can not be 
seen under the microscope and the physical mixtures transfer to the amorphous solid dispersions.  
 
Figure 36. polarized light hot stage microscopy pictures of heating the physical  mixtures to 180 °C.  
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4.3.2. Preparation of the filaments 
 
Figure 37. the extrusion torque and die pressure for different extrusion formulations. 
In this work the standard screw design was applied for all the material extrusion process, 
which allows the balance between the distributive and dispersive extrusion to grantee the 
transformation of crystalline form to amorphous solid dispersion as well as the uniformity. The 
extrusion torque and die pressure were recorded and shown in figure 37. The torque represent 
extrudability of the materials and also indicating the miscibility of the API and polymer matrix, as 
mentioned in the DSC analysis part, the APAP should be more easily mixed with the  
Filaments with adequate physicochemical and mechanical properties were successfully 
produced by the HME process. The diameter of the filaments were around 1.75 mm. The process 
temperature, torque and die pressure was recorded when the extrusion reaches the steady states. 
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The torque was used to evaluate the extrudability of the materials and can also represent the 
flexibility of the materials. As observed, the drug loaded filaments were flexible compared to the 
filament without drug loading; In addition, the HPMC filaments are more flexible than the 
HPMCAS filaments. And the die pressure in this work can be used to represent the hardness of the 
filaments, and similar observation obtained as the torque studies: filaments without drug loaded 
are harder and HPMCAS filaments are harder than HPMC formulation.  
 
Figure 38. the SEM graphs shows the surface of the a) HPMC and b) HPMCAS filaments. 
From the figure 37, it seems the HPMC matrix is more extrudable than the HPMCAS 
formulations, however, the rough surface and porous structure are observed from the SEM pictures 
(figure 38). It may because of the moisture contents in the HPMC formulation which cause the air 
a b 
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bubbles during the extrusion process. The rough surface of the filaments also affects the 3D printed 
structures as will and the shell also observed has rough surface and micro porous structures (figure 
38a).  
As shown in figure 37, the lowest extrudable temperature, extrusion torque and die pressure 
of drug loaded matrix were reduced compared to the polymer only. It may because of the APAP 
interact with the polymer matrix and formed a hydrogen bonds and act as the plasticizer during the 
extrusion process, which reduced the glass transition temperature (Tg) of the system. As mentioned 
in section 4.3.1 of this chapter, the APAP was dissolve or dispersed into the polymer matrix and 
transform from the crystalline to amorphous can be proved by the DSC studies. 
 
Figure 39. the raw in-line NIR spectra collected during the extrusion process.  
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Figure. 40. The 2nd derivative of the raw spectra collected during the extrusion process. 
As an invaluable in-process analytical tool, Fourier transform near-infrared (FT-NIR) 
spectroscopy in conjunction with multivariate analysis (MVA) techniques, such as partial least 
squares (PLS) in this work, has been used to provide near real-time chemical information. The 
extrudates spectra are continuously collected by the in-line fiber optical probe while the pure API 
and polymers were collected using the integer sphere. All the spectra are present in figure using a 
common scale.  
According to the previous work, the FT-NIR signal response to the HME parameters 
changing, which shows on the spectra graph is that the signal intensity is different under different 
process parameters or drug loading[94]. The spectra collected during extrusion of each formulation 
were perfectly overlap which indicating the homogeneity of the extruded filaments.  
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As showing in figure 39, materials showed different peaks and three potential wavenumber 
range (8780-9230 cm-1, 6500-7430 cm-1, and 5850-6250 cm-1) can be identified as the APAP 
signature peaks, because the APAP shows high signal intensity while the polymers did not. It can 
be used to analysis the interaction of the APAP and polymer matrix during the HME process. The 
identical peak area can be used to isolated the APAP peaks from the molten mixtures to represent 
the signal of the APAP. In order to, see the interaction during the HME process clearly, second 
order derivative of all curves were adopted. The 6500-7430 cm-1 was demonstrated in figure, for 
an example, peaks around 6100 cm-1 and 6030 cm-1 can be considered as the signal from the APAP, 
however, the peak of the spectra of the molten mixtures are both shifting to the lower energy side, 
which could possibly be the formation of the hydrogen bonds leads to the attenuation of the glass 
transition T of the system. 
4.3.3. Tablet morphology studies  
Due to the second thermal process, 3D printed tablets showed different physiochemical 
properties compare to the direct compressed milled extrudates tablets. As showing in figure 41, 
the particulates can be observed from the direct compressed tablets, especially the HPMCAS HG 
tablets. However, due to the  hygroscopicity of the HPMC formulation, the particulates were 
compressed and more uniform than the HPMCAS HG tablets.  According to the SEM results, 
compared with PM tablets, there is no single particulates can be seen in 3dp tablets, which can be 
considered as a continuous structured object with homogenized composition. As discussed in 
section before, the HPMC has rough surface which affects the appearance of the 3D printed tablets 
as well. On the contrary, the 3D printed HPMCAS HG tablets showed more smooth surface and 
better appearance.  
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Figure 41. the SEM pictures of the 3D printed tablets shown the porous structure of the shell and 
the condense core.   
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Figure 42. the SEM pictures of direct compressed a) HPMCAS matrix and b) HPMC matrix tablets. 
Table 8. the weight, dimensions and density of the 3D printed and direct compressed tablets. 
 Weight (mg) Diameter (mm) Height (mm) Density (mg/mm3) 
Core-shell 286.13±1.73 12.39±0.12 4.53±0.04 0.9253 
3DP shell 198.46±2.65 
12.27±0.11 
(5.84±0.03)* 
4.51±0.02 0.9545 
3DP core 100.01±7.00 5.84±0.06 4.40±0.08 1.0566 
DC HPMC 197.33±3.06 8.00±0.01 3.65±0.07 1.0737 
DC HPMCAS 197.67±2.08 8.00±0.00 4.37±0.09 0.9005 
*the inner diameter of the shell 
The cylinder shaped tablets volume can be calculated as follows:  
 
𝑉 =
𝜋𝐷2
4
∗ ℎ Eq 13 
a b 
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where D and h are the diameter and thickness of the tablets, respectively. Thus, the 
theoretical density of a tablet was calculated according to the following equation: 
 
𝜌 =
𝑚
𝑉
=
4𝑚
𝜋𝐷2 ∗ ℎ
 Eq 14 
where m is the weight of the tablet. The density of the HME-generated filaments was 
calculated using the same equation. The 3D printed tablets has specific 3D structure, which all 
have porous structure or combine two totally different parts. The shell tablets is tube shaped with 
50% infill, so the density was calculated using equation 3: 
 
𝑉 = (
𝜋𝐷2
4
∗ ℎ −
𝜋𝑑2
4
∗ ℎ) ∗ 50 % Eq 15 
where D is the outside diameter and d is the inside diameter. The core structure was 80 % 
filled, so the volume is: 
 
𝑉 =
𝜋𝐷2
4
∗ ℎ ∗ 80% Eq 16 
The core-shell structured tablets has 77.8% volume is shell with 50 % infill density and 
22.2% volume is core with 80% infill density, so the theoretical volume is:  
 
𝑉 =
𝜋𝐷2
4
∗ ℎ ∗ (77.8% ∗ 50% + 22.2% ∗ 80%) Eq 17 
The volume of the 3D printed shell, core and core-shell tablets obtained from the equation 
15-17 was then substituted into equation 17 for the density estimation.   
As shown in Table 8 the theoretical density of 3DP tablets was much higher than that of 
unprinted filaments. In addition, tablets with high hardness and density values are expected to have 
delayed dissolution and slow drug release after administration. In the geometric study, the tablets 
had only small variations in weight and dimensions, which demonstrate the good reproducibility 
of the 3D printing process.  
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4.3.4. In vitro drug release studies  
According to the previous work, both HPMC and HPMCAS matrix will formed hydrogel 
which can control the drug release rates. In this work, the shell (HPMC) has more porous structure 
which should formed the hydrogel faster than the condense core (HPMCAS HG) structures. In 
order to maintain the same size and weights, the direct compressed tablets were prepared with high 
pressure. Even though there has particulates in the direct compressed tablets, they are not 
disintegrate during the dissolution studies and the high density which will dramatically slow down 
the formation of the hydrogel.  
The drug dissolution rates of tablets prepared by 3D printing and direct compression were 
evaluated. As discussed in section 3.1, the APAP was dispersed or dissolved into the polymer 
matrices and formed solid dispersions or solutions during the HME process. The drug release rates 
from tablets prepared by different techniques influenced by the 3D geometric structure and 
composition, and the following were happened during the in vitro drug release study: 
• The dissolution mechanism of both 3D printed and direct compressed tablets were swallow 
and erosion, neither of them can disintegrate due to the cellulose polymer matrix. So, a 
steep concentration gradient formed at the media/tablet interface once the tablets contacted 
the dissolution media. Here, water acted as a plasticizer and reduced the glass transition 
temperature (Tg) of the contact interface section. Once the system Tg reached the 
temperature of in vitro study, the matrix transformed to hydrogel [59]. 
• The HPMC and HPMCAS matrix swelled and formed hydrogel while the media were 
penetrating, which changed the drug concentration at the media/tablet interface. Media 
penetrate through polymer matrix was the most important rate-controlling step during the 
dissolution study. The media took longer to penetrate through the direct compressed tablets 
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because they and the core because they have high density than through the porous shell 
structures. 
• The APAP to diffuse from the media/tablet interface to the hydrogel due to the 
concentration gradients, and thus into the dissolution media. HPMC has higher solubility 
than the HPMCAS matrix in the pH 6.8 SIF, which indicating the drug release rates from 
the HPMCAS matrix would be slower than from the HPMC matrix. 
• In addition, the more porous structure was less restrictive for drug diffusion upon drug 
depletion, the APAP will release rapidly from the HPMC shell; conversely, due to the 
condense structure and HPMCAS matrix, the APAP was slowly released from the core. 
As expected, all direct compressed tablets has extend drug release rate because its high 
density. Faster drug release was observed with shell structure, which released 80% drug in 2 h, 
while the core structure tables release APAP over an extended time period (<80% after 7 h, 
respectively).  
 
Figure 43. the drug release profiles of the 3D printed tablets and direct compressed tablets.  
93 
 
In order to see the drug release rates changes along with the time, the dissolution cure were 
showed in the total amount released (mg) to the time (figure 43b). As shown in the curve, the core-
shell structured tablets released drug more than the shell and core only because both the shell and 
core contributes to the total amount drug released from the core-shell tablets. There is no doubt 
that shell structure release drug faster and more than the core structure during the 420 min drug 
release studies. 
Figure 44. the drug release rates of the 3D printed tablets, shell structure and core. 
To have a clear vision of the drug release rates, the 1st order of dissolution curve was 
deriveted and shown in figure. The drug release rates from the core-shell tablets was fast at 
beginning, and the rates decrease due to the amount of the APAP released from the tablets and the 
decrease of the concentration gradients. When the shell structure reaches the equilibrium the drug 
release rate becomes slow and steady, which contributes to the extended therapeutic effects. The 
shell only structure releases drug fast at the beginning as well, but it becomes zero when the 
hydrogel reaches the equilibrium. The core only structure releases drug slowly but in a constant 
rates always. 
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4.4. Conclusion  
In this work, the 3D printable amorphous filaments were successfully prepared and 
evaluated. Also the 3D core-shell structured tablets were acquired by both HME and FDM based 
3D printing technologies. The in vitro dissolution profiles demonstrated that the drug release from 
the core-shell structured tablets was fast at the first 1h which contributes to fast effectives when 
the oral dosage was administrated, then the drug release rate decrease and become constant due to 
the condense extend core structure which contributes to the long effectiveness for the oral dosages. 
The work also demonstrated that the bright future of combining the HME and 3D printing 
technology for personalized dosages preparation.    
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Conclusion 
As an emerging technology in the pharmaceutical industry, there are many challenges to 
3D printing. Some review articles have already raised points worthy of consideration. Liaw et al. 
reviewed the FDA regulations and challenges of 3D printing [102]. Preis et al. systematically 
reviewed the current status of the 3D-printed drug for children and the challenges encountered 
[103]. Our current research focuses on the challenges of the materials, equipment, and processes 
of 3D printing for personalized drug delivery systems. 
Most 3D printing platforms were initially developed for applications in industries other 
than pharmaceutical, and most materials used in the printing were not pharmaceutical grade. To 
develop personalized drug delivery systems using 3D printing technologies, pharmaceutical 
scientists have two important considerations: 1) find appropriate materials for the different types 
of 3D printing, and 2) maintain the desired properties after the printing process. 
This thesis was organized systematically to present the combination of hot melt extrusion and 
additive manufacturing in development of pharmaceuticals. The additive manufacturing/3D 
printing is an emerging technology at infancy but has a tremendous potential in development of 
pharmaceutical products. This promising potential to develop the personalized medication is a 
revolutionary change in compounding the dosage forms with tailored dose, especially for narrow 
therapeutic drugs. This would have profound effect on society and industry. However, the 
appropriate regulations and policies must be developed for future research in this arena. 3D 
printing has provided new prospects for various industries in production paradigm and range of 
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manufacturing industrial to retail and decentralized manufacturing. This additive manufacturing 
has exceptional applications which need to be exploited in manufacturing sector. Nevertheless, the 
usage of different 3D printing technologies has increased in various industries in the recent past, 
it requires advancements (reducing production time, printers cost and printer materials) to replace 
the conventional production methods. Wohler’s report in 2014 reveals that revenue for additive 
manufacturing globally rise four folds from $5 billion in 2016 to $21 billion in 2021. This suggests 
a huge market potential for additive manufacturing in near future. 
In this thesis, we successfully conjugated the HME and 3D printing technology as an efficient and 
economical platform for personalized or patient focused dosages development. Moreover, a 
considerable work has been done to screen the 3D printable filaments for such formulation 
development. And also the comprehensive understanding the 3D printed structures with their in 
vitro drug release profiles were obtained. Based on these achievements, the optimization of the 
oral drug administration has been achieved by specific core-shell structure design. This thesis 
clearly demonstrated that the promising future of combining HME and 3D printing technologies 
for the future novel drug delivery system development. 
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